output
listlengths 0
91
| instruction
stringlengths 230
1.72k
| input
stringclasses 1
value |
|---|---|---|
[
{
"end_pos": 9,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 7
},
{
"end_pos": 34,
"label_type": "手术",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 42,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 44,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 43
},
{
"end_pos": 47,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 70,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 138,
"label_type": "手术",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 191,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 256,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 291,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 260
},
{
"end_pos": 470,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 469
},
{
"end_pos": 474,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 473
},
{
"end_pos": 515,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 508
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因罹患“胃癌”于2013-10-29在我院予行全麻上胃癌根治术，，术中见：腹腔内腹水，腹膜无转移，肝脏未触及明显转移性灶，肿瘤位于胃体、胃底部，小弯侧偏后壁，约5*4*2CM大小，肿瘤已侵达浆膜外，第1、3组淋巴结肿大，肿瘤尚能活动，经探查决定行全胃切除，空肠J字代胃术。手术顺利，术后积极予相关对症支持治疗；，后病理示：胃底、体小弯侧低分化腺癌，部分为印戒细胞癌图像，蕈伞型，面积5.2*3.5CM，局部侵达粘膜上层，并于少数腺管内查见癌栓。双端切线及另送“近端切线”未查见癌。呈三组（5/13个）淋巴结癌转移。一组（7个）、四组（13个）、五组（1个）、六组（4个）淋巴结未查见癌。，癌组织免疫组化染色示：ERCC1（+）、β-TUBULIN-III（+）、TS（-）、RRM1（-）、TOPOII阳性细胞数约20%、CERBB-2（2+） 。依据患者病情及肿瘤病理与分期继续术后辅助性化疗指征存在，患者及家属拒绝化疗。自术后出院以来，患者一般情况保持良好；无发热，偶有恶心，无呕吐，无反酸、嗳气，无明显进食不适，偶有进食后轻微腹胀，无腹痛。现患者为行进一步复查并必要时适当处理而再来我院就诊，门诊依情以“胃恶性肿瘤术后”收入院。目前患者精神及情绪状态良好，食欲较术前明显减少，饮食可，夜间睡眠后；今8个月体重减轻18KG。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 166,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 158
},
{
"end_pos": 248,
"label_type": "药物",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 261,
"label_type": "药物",
"overlap": 0,
"start_pos": 257
},
{
"end_pos": 275,
"label_type": "药物",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 336,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 331
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者3月余前于我院诊断为“直肠癌”，于2015-10-26在全麻上行腹腔镜直肠癌根治术，，术后病理示：，201518502：（直肠）腺癌（中度分化），浸润溃疡型，体积2.7*2*0.8CM，侵达浆膜。 双端切线及另送“近切线”、“远切线”未查见癌。 肠壁一站（6个）、中间组（3个）、中央组（3个）淋巴结未查见癌。低级别腺管状腺瘤。，免疫组化染色示：TS部分（+）、SYN（-）。，术后病理分期：PT3N0M0，II期，DUKES B。依情2015-11-08.2015-12-09给予奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1G D2-6 静滴，同时辅以镇吐、升血、免疫调节等对症支持治疗。化疗过程总体顺利。现为复查化疗来我院，门诊以“直肠癌术后”收入院。目前患者精神好，食欲及饮食好，夜间睡眠良好，小便正常，大便4-5次/天，基本成形。否认近期明显体重变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 37,
"label_type": "手术",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 103,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 139,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 154,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 169,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 158
},
{
"end_pos": 269,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 268
},
{
"end_pos": 271,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 270
},
{
"end_pos": 302,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 297
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“结肠癌”于2012-12-13在我院于全麻上行右半结肠切15除术，手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好，切口愈合良好，，术后病理：13862.2012结肠腺癌（中度分化），溃疡型，面积6.5*3.5，侵达浆膜脂肪组织。双端切线未查见癌。结肠腺管状腺瘤。呈肠壁一站（1/5个）淋巴结癌转移。肠壁二站（3个）淋巴结未查见癌。，免疫组化染色示癌组织：ERCC1(+)、TS少数细胞（+）。（PT4AN1M0，IIIA，DUCKS C）。后患者恢复好出院，术后给予化疗2周期。 院外期间患者一般情况好，无恶心，无腹痛腹胀胀不适，现患者为行复查及化疗再次来院就诊，门诊以“结肠癌术后”收入院。 近期患者精神可，饮食可，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 14,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 34,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 71,
"label_type": "手术",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 83,
"label_type": "手术",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 139,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
},
{
"end_pos": 195,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 189
},
{
"end_pos": 205,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 220,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 211
},
{
"end_pos": 242,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 375,
"label_type": "药物",
"overlap": 0,
"start_pos": 371
},
{
"end_pos": 378,
"label_type": "药物",
"overlap": 0,
"start_pos": 376
},
{
"end_pos": 397,
"label_type": "药物",
"overlap": 0,
"start_pos": 392
},
{
"end_pos": 400,
"label_type": "药物",
"overlap": 0,
"start_pos": 398
},
{
"end_pos": 469,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 468
},
{
"end_pos": 472,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 471
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余因中下腹部闷痛不适伴排黑便于我院就诊，诊断为“胃癌”，于2014年06月06日在全麻上行“腹腔镜辅助上根治性远端胃大部切除术（ROUX-Y吻合术D2）”手术顺利。术后病理（201417771），：“（远端胃）胃体小弯早期（IIC型）低分化腺癌，部分为印戒细胞癌，侵及粘膜上层，手术标本下、上切端及另送（下切端）均未见癌浸润。找到小弯淋巴结5个，大弯淋巴结5个，幽门下淋巴结18个，幽门上淋巴结3个，及另送（第8P组）淋巴结2个，均未见癌转移。另送（胃右动脉根部淋巴结）为脂肪、脉管及神经组织。，免疫组化结果：CK(L)（+++），CD68（组织细胞+），KI67（50%+）”，术后给予对症、抗感染治疗，恢复良好,伤口愈合良好。分别于2014.07.16、2014.08.13、2014.09.17、2014.10.29予“奥沙利铂（齐沙）150MGIVGTTD1+替吉奥胶囊（艾奕）40MGPOBIDD2-15”方案行术后第1、2、3、4周期化疗，化疗过程顺利。今为第5周期化疗再次入院。自下次出院后饮食、睡眠可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 40,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 42
},
{
"end_pos": 69,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 76,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 86,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 99,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 174,
"label_type": "药物",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 191,
"label_type": "药物",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 194,
"label_type": "药物",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 211,
"label_type": "药物",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 246,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 269,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 317,
"label_type": "手术",
"overlap": 0,
"start_pos": 302
},
{
"end_pos": 338,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 387,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 445,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 439
},
{
"end_pos": 457,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 451
},
{
"end_pos": 469,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 463
},
{
"end_pos": 480,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 474
},
{
"end_pos": 498,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 487
},
{
"end_pos": 510,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 503
},
{
"end_pos": 610,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 604
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前5月余因“反复返酸、嗳气7年”就诊我院，，行胃镜检查示：“1.胃窦癌2.慢性萎缩性胃炎”，，病理示：“胃管状腺癌II-III级”，下腹部平扫+，增强示：“胃肿瘤，伴腹腔、腹膜后多发淋巴结肿大”，考虑肿瘤局部较晚期，遂于2015.04.18、2015.05.11、2015.06.02、2015.06.29、2015.08.02予“安素泰210MGIVGTTD1+奥沙利铂（艾恒）150MGIVGTTD2+希罗达1000MGBIDPOD1-14”方案新辅助化疗，辅以止吐、制酸、保胃、保肝、营养支持等治疗。化疗后未见明显骨髓抑制，一般情况尚可。并于入院前1月余（2015.09.01）全麻上行“腹腔镜上根治性远端胃大部切除术”。术顺，术后恢复可，，术后病理：(远端胃)，：胃体及胃窦小弯侧早期隆起型（0-I型）低黏附性癌，印戒细胞癌为主，部分为低分化腺癌及未分化癌，浸润脉管及神经组织，脉管内见癌栓，侵及黏膜上层。标本下切端、上切端及另送(下切端)，均未见癌浸润。找到小弯侧淋巴结0/13个，大弯侧淋巴结2/10个，幽门下淋巴结1/4个，幽门上淋巴结5/6个，另送(胃右动脉根部）淋巴结2/8个，(胃壁)淋巴结0/4个，见癌转移。，免疫组化染色结果：CK(PAN)（+++），E-CADHERIN（+++），CDX-2（+++），CGA（+），CD56（-），SY（-），HER-2（-）。门诊拟“胃窦术后化疗”收入院。自发病以来，精神、睡眠可，食欲一般，大小便如常，体重无明显变化。 | |
[
{
"end_pos": 33,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 79,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 90,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 95,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 135,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 146,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 160,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 222,
"label_type": "药物",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 236,
"label_type": "药物",
"overlap": 0,
"start_pos": 234
},
{
"end_pos": 252,
"label_type": "药物",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 256,
"label_type": "药物",
"overlap": 0,
"start_pos": 253
},
{
"end_pos": 283,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 339,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 336
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，入院前1月余因“进行性吞咽困难1年”就诊我院，，查胃镜示：，食管占位伴狭窄：癌不能排除，，活检病理示：“鳞状下皮呈乳头状增生，部分鳞状下皮呈低级别下皮内瘤变”，完善颈胸腹部，CT：食管下段部分管壁不规则增厚，考虑为食管癌，伴右侧锁骨下窝、食管旁沟及纵膈内多发淋巴结转移；另病变下缘一食管憩室。考虑食管癌伴纵隔淋巴结转移，为提高手术切除率，建议行术前新辅助化疗，告知患者家属，其表示理解，遂于2016.12.26、2017.01.16按氟尿嘧啶3000MG微量泵泵入+洛铂50MGIVGTTD2+多西他赛（泰索帝）120MGIVGTTD2”第1、2周期化疗，辅以保肝、止吐、制酸、营养支持等治疗，疗程较为顺利，未见明显化疗副反应。现为求进一步治疗，遂再次就诊我科，门诊拟“食管癌术前化疗”收住院。末次出院以来，精神、睡眠一般，大小便如常，体重无明显增减。 | |
[
{
"end_pos": 10,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 40,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 74,
"label_type": "手术",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 134,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 204,
"label_type": "药物",
"overlap": 0,
"start_pos": 200
},
{
"end_pos": 221,
"label_type": "药物",
"overlap": 0,
"start_pos": 218
},
{
"end_pos": 233,
"label_type": "药物",
"overlap": 0,
"start_pos": 230
},
{
"end_pos": 293,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 286
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者4月余前因“下腹疼痛不适，伴反酸、嗳气”在我院完善相关检查后确诊“胃体胃窦癌”，于2015-10-10在全麻上行“胃癌根治术（远端胃大部分切除）”，术程顺利，术后预防感染支持对症等处理，恢复好，切口甲级愈合。术后病理示：“胃体胃窦癌 PT4AN3AM0 IIIC期。”于2015-11-05、2015-12-07、2016-01-14、2016-02-15、2016-03-18日在我院行SOX（奥沙利铂 100MG IVDRIP+替吉奥 60MG QN+替吉奥 40MG QM）方案化疗，化疗期间患者未诉特殊不适，未见明显副反应。现在为上一步治疗来我院门诊就诊，拟“胃癌综合治疗后”收入我科。术后出院至今患者精神尚可，食欲为半流为主，大小便正常，体重增加约2KG。 | |
[
{
"end_pos": 7,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 4
},
{
"end_pos": 33,
"label_type": "手术",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 42
},
{
"end_pos": 68,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 97,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 111
},
{
"end_pos": 116,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 137,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 160,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 180,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 190,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 195,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 228,
"label_type": "手术",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 230,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 229
},
{
"end_pos": 238,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 244,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 243
},
{
"end_pos": 401,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 400
},
{
"end_pos": 404,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 403
},
{
"end_pos": 415,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 414
},
{
"end_pos": 418,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 417
},
{
"end_pos": 451,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 444
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因壶腹部占位于2016-07-22日在我科行胰十二指肠切除术+肝囊肿开窗引流+肝活检术，，术后病理示：壶腹部鳞状细胞癌（低度分化），体积4*2.8*2.5CM，侵达十二指肠粘膜层，侵及胰腺组织，于较多脉管内查见癌栓。胆总管、胃、十二指肠切线及胰腺切除面未查见癌；胆总管残端切线于少数脉管内查见癌栓。呈胰腺周围淋巴结（1/2个）癌转移。胃周围（2个）淋巴结未查见癌。慢性胆囊炎。（肝囊肿右、左）纤维性囊壁样结构，慢性发炎，局部衬覆单层立方下皮。（肝活检）肝组织一块，部分肝细胞淤胆，肝被膜及汇管区较多炎细胞浸润。，免疫组化染色示：CK5/6（+）、P63（+）、CK7（-）、CK20（-）、SYN（-）。患者术后恢复良好，无特殊不适，2016.10.6入院行静脉化疗治疗，2016.12.5入院行介入及静脉化疗，2017.2.16入院行静脉化疗，治疗结束后出院。患者出院后，自觉全身乏力，无明显腹胀、腹痛，无恶心、呕吐，无心慌、胸闷等不适。今患者为术后综合治疗，来我院就诊，门诊以“胰十二指肠术后”收入院。 患者自术后以来，神志清，精神好，饮食可，睡眠可，大小便无异常，体重略增加。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 84,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 155,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 283,
"label_type": "药物",
"overlap": 0,
"start_pos": 281
},
{
"end_pos": 292,
"label_type": "药物",
"overlap": 0,
"start_pos": 288
},
{
"end_pos": 303,
"label_type": "药物",
"overlap": 0,
"start_pos": 300
},
{
"end_pos": 342,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 345,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 344
},
{
"end_pos": 363,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 361
},
{
"end_pos": 404,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 400
},
{
"end_pos": 426,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 425
},
{
"end_pos": 429,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 428
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前3年余于我院诊断为胃癌，于2012-04-11在全麻上行腹腔镜上根治性全胃切除术，术后病理示(201210103)，：食管胃交界溃疡型管状腺癌II－III级，侵出浆膜层，手术标本下、上切端及另送（下切端）均未见癌浸润。找到贲门左淋巴结1/15个，小弯淋巴结0/2个，大弯淋巴结0/1个，幽门下淋巴结0/5个，幽门上淋巴结0/5个，及另送（第8组）淋巴结0/4个见癌转移。，免疫组化：KI67（30%+），P53（-），CD56（-），SY（-），CGA（-），CK18（+++）。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。术后再入院行洛铂50MG+表柔比星100MGD1+希罗达1500MGBIDD1-D14方案化疗6周期，未见明显化疗反应，2天前,自诉腹痛,脐周明显,呈阵发性,可自行缓解,伴肛门停止排气排便.现感症状加重,无明显缓解方式,为求进一步诊治遂来我院，门诊拟腹痛待查收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 54,
"label_type": "手术",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 59,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 77,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 84,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 106,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 208,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 211
},
{
"end_pos": 268,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 263
},
{
"end_pos": 289,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 302,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 294
},
{
"end_pos": 483,
"label_type": "药物",
"overlap": 0,
"start_pos": 479
},
{
"end_pos": 500,
"label_type": "药物",
"overlap": 0,
"start_pos": 496
},
{
"end_pos": 541,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 536
},
{
"end_pos": 566,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 565
},
{
"end_pos": 569,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 568
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前3月因“直肠癌”就诊我院，于2016年11月10日在全麻上行腹腔镜上直肠根治术（DIXON手术）,探查腹腔内无明显出血，没有明显粘连，无明显腹水，肿瘤位于腹膜返折下5CM对系膜侧，侵及浆膜层，未形成肠梗阻，近端无扩张，周围未见明显肿大淋巴结。术顺,术后予预防感染、制酸、补液、营养支持、增强免疫力等处理，术后恢复可。术后病理（201641027），：（直肠），：直肠隆起型中分化管状腺癌，小灶区为黏液腺癌，侵犯肠壁全层，脉管见癌侵犯，未见明确神经侵犯，手术标本下、上切端及另送（下切端）、（上切端）未见癌浸润。找到肠周淋巴结3/14枚及另送（肠系膜上动脉根部）淋巴结0/4枚，（中间组）淋巴结1/9枚，见癌转移。，免疫组化：肿瘤细胞示CK7（-），CK20（+++），KI67（60%+）。MLH-1（++），MSH-2（+++），MSH-6（+++），PMS-2（+）提示该病例肿瘤微卫星稳定(MSS)，请结合临床。检测到KRAS基因存在G13D突变。未检测到NRAS基因热点突变。未检测到BRAF基因V600E突变。于2016-12-10予“奥沙利铂200MGIVGTTD1+卡培他滨1500MGBIDD1-D14”方案化疗，此次为化疗再次就诊我院，门诊拟直肠癌术后化疗收入院。自下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 23
},
{
"end_pos": 65,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 62
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 86,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 140,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 148,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 157,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 162,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 176
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 201,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 219,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 217
},
{
"end_pos": 253,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 249
},
{
"end_pos": 293,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 288
},
{
"end_pos": 350,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 367,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 360
},
{
"end_pos": 390,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 384
},
{
"end_pos": 398,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 391
},
{
"end_pos": 444,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 443
},
{
"end_pos": 448,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 446
},
{
"end_pos": 485,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 477
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者12天前因“子宫内膜复杂性增生”在我院行全子宫切除术+两侧输卵管切除术+盆腔粘连松解术。，术中探查: 部分大网膜粘连于左前腹壁，分离粘连后见肝脏表面光滑，大网膜及肠管表面未见明显异常。盆腹腔内少量血性积液。子宫前位，约2个月妊娠大小，表面光滑，局部质硬，呈腺肌病样改变，子宫后壁上段与部分肠系膜粘连，右侧卵巢粘连于子宫右后壁，左侧卵巢萎缩，粘连于子宫左后壁和侧腹膜。两侧输卵管外观正常。，术中腹腔冲洗液送快速病理检查结果提示：（腹腔冲洗液）离心涂片查见大量间皮细胞及少量淋巴细胞、中性粒细胞。子宫内膜呈孕激素类药物治疗后改变，冰冻切片局部查见少许复杂性增生的内膜。未累及子宫颈外口切线。手术顺利，，术后常规病理回示：子宫内膜复杂性增生，部分腺体呈高级别下皮内瘤变，部分区域为高分化子宫内膜样腺癌，位于粘膜内，未累及子宫颈颈管内口，未累及底部切除面及外口残端切线。慢性子宫颈炎。（两侧）输卵管组织。，免疫组化染色示：ER（+）、PR（+）、P53少量（+）。建议进一步治疗。患者现无腹痛及阴道流血，无其他不适。今日患者为行进一步治疗来院就诊，门诊以“子宫内膜病变术后”收入院。 患者自发病以来，一般情况可，精神、睡眠良好，饮食一般，大小便无异常，体重无明显改变。 | |
[
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 45,
"label_type": "手术",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 51
},
{
"end_pos": 58,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 62,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 65,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 79,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 110,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 128,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 143,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 140
},
{
"end_pos": 152,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 167,
"label_type": "手术",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 179,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 193,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 202,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 201
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 380,
"label_type": "药物",
"overlap": 0,
"start_pos": 377
},
{
"end_pos": 397,
"label_type": "药物",
"overlap": 0,
"start_pos": 393
},
{
"end_pos": 414,
"label_type": "药物",
"overlap": 0,
"start_pos": 410
},
{
"end_pos": 434,
"label_type": "药物",
"overlap": 0,
"start_pos": 431
},
{
"end_pos": 478,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 471
},
{
"end_pos": 502,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 501
},
{
"end_pos": 505,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 504
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前20余日于我院诊为乙状结肠癌，于2015-10-21在全麻上行乙状结肠癌根治术，，术中见：腹腔内无明显腹水，腹腔、盆腔、大网膜无明显转移结节，肝脏质地大小正常，未触及肿物，胆囊未触及结石。肿瘤位于乙状结肠上段，约6×5㎝，未形成肠梗阻，近端肠管无扩张，周围可见少许肿大淋巴结。诊断“乙状结肠癌”，遂决定行“乙状结肠癌根治术。术后病理示.(乙状结肠)，：肠溃疡型管状腺癌II级，侵犯肠壁全层及肠周脂肪组织，侵犯神经组织，未见肯定脉管侵犯，手术标本下、上切端及另送（下切端）（上切端）均未见癌浸润；找到肠周淋巴结9个，未见癌转移。2.该病例检测到KRAS基因12号密码子GLY12ASP突变。3.该病例未检测到BRAF基因V600E突变。，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。2015-11-21行第1周期化疗，具体方案为“沙利铂140MGD1IVGTT+氟尿嘧啶700MGD1IVGTT+氟尿嘧啶4200MGD1-D2微量泵泵人+亚叶酸650MGD1-D2IVGTT”，此次为术后第2次化疗再次就诊我院，门诊拟乙状结肠癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 49,
"label_type": "手术",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 58,
"label_type": "手术",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 129,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 150,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 180,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 202,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 236,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 228
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 262,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 288,
"label_type": "药物",
"overlap": 0,
"start_pos": 284
},
{
"end_pos": 302,
"label_type": "药物",
"overlap": 0,
"start_pos": 295
},
{
"end_pos": 306,
"label_type": "药物",
"overlap": 0,
"start_pos": 303
},
{
"end_pos": 316,
"label_type": "药物",
"overlap": 0,
"start_pos": 313
},
{
"end_pos": 344,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 347,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 417,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 391
},
{
"end_pos": 424,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 420
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2个月因诊断为“胃癌”，于2014年12月09日在我院全麻上行“根治性远端胃大部切除术，ROUX-Y吻合，D2，R0”，术顺，术后予以制酸、保肝、增强免疫力、抗肿瘤、抗感染、抑制消化液分泌及对症支持治疗。术后病理（201443329），：(远端胃)，：胃角溃疡型粘液腺癌，部分为印戒细胞癌，侵出浆膜外，手术标本下、上切端均未见癌浸润，找到小弯淋巴结2/14个，大弯淋巴结0/7个，幽门上淋巴结2/15个，见癌转移。（201443369），：找到(第7组)淋巴结0/1个、(第8组)淋巴结2/2个、(第9组)淋巴结0/1个，见癌转移。2015.01.09按“奥沙利铂150MGD1多柔比星脂质体（里葆多）40MGD2希罗达1000MGD1-14”行第1周期术后辅助化疗，辅以护胃，保肝，止呕吐等对症处理。1天前无明显诱因出现发热，无寒战，无肢体抽搐，遂来我院就诊，门诊拟“胃角溃疡型粘液腺癌（PT4AN2M0IIIB期）术后化疗，发热待查”收住入院。自发病以来，患者精神、饮食、睡眠尚可，大小便正常，体重未见明显变化。 | |
[
{
"end_pos": 28,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 20
},
{
"end_pos": 77,
"label_type": "手术",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 87,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 139,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 126
},
{
"end_pos": 172,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 179,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 196,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 188
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 231,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 223
},
{
"end_pos": 247,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 260,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 273,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 437,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 421
},
{
"end_pos": 461,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 460
},
{
"end_pos": 464,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 463
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，入院前8天（2013.12.06）因“宫颈鳞癌IB1期”就诊我院全麻上行行腹腔粘连松解术+部分大网膜切除术+广泛全子宫+两侧卵巢移位术+盆腔淋巴结清扫术，术前查，CA125：18.42U/ML，术后病理回报（201338627），：1、（全子宫），：宫颈浸润型鳞状细胞癌II级，侵及肌层（浸润深度＜1/2宫颈全层），脉管内见癌栓，手术标本阴道切端及两侧宫旁组织均未见癌浸润。宫体肌间平滑肌瘤，宫内膜呈增生状态。2、找到（右髂总）淋巴结0/6个，（右盆腔）淋巴结2/40个，（右侧腹股沟）淋巴结0/2个，（左髂总）淋巴结0/9个，（左盆腔）淋巴结1/16个见癌转移。3、（大网膜），：送检网膜组织未见癌细胞种植转移。，免疫组化：KI67（40%+），CK5/6（+++），CK(H)（+++），P63（++++），CEA（++），CK18（-），术后予补液、营养支持等治疗，恢复良好，伤口愈合II/甲。今为行第1次化疗，再次就诊我院，门诊拟“宫颈鳞癌（IB1期，II级）术后”收入院。下次出院以来，精神、睡眠、饮食好，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 10,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 52,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 118,
"label_type": "药物",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 143,
"label_type": "药物",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 206,
"label_type": "手术",
"overlap": 0,
"start_pos": 193
},
{
"end_pos": 257,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 262,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 374,
"label_type": "药物",
"overlap": 0,
"start_pos": 370
},
{
"end_pos": 395,
"label_type": "药物",
"overlap": 0,
"start_pos": 391
},
{
"end_pos": 439,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 432
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者7月前因“下腹腹胀伴反酸”至我院就诊，完善相关检查，诊断“胃体胃窦癌(CT4N2M0,IIIB期)”，建议先行化疗，患者及家属表示理解同意，遂于2015-5-26、2015-06-19、2015-07-13分别予XELOX(希罗达 1250MG BID PO D1-14+奥沙利铂150MG IVDRIP Q3W)化疗三程,过程顺利，无明显副反应，后于2015-08-24在全麻上行胃癌根治术（远端胃大切），术程顺利，术后预防感染支持对症等处理。，术后病理示：胃中至低分化管状腺癌（LAUREN，分型：肠型），浸润至胃壁浆膜上层，可见神经束侵犯，未见明确脉管内癌栓；肿瘤消退分级（MANDARD），：TRG4；网膜组织未见癌；LN（-）；YPT3N0M0，IIA期。术后恢复可，于2015-10-10、开始采用XELOX化疗方案化疗（奥沙利铂150MG Q3W IVDRIP+卡培他滨1250MGBID*14天）一程，过程顺利。现为行上程化疗来我院就诊，拟“胃癌综合治疗后”收入我科。自下次出院以来，患者精神可，食欲尚可，大小便正常，体重无明显上降。 | |
[
{
"end_pos": 40,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 50,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 45
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 71,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 75,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 97,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 105,
"label_type": "手术",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 132,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 157,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 160,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 198,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 233,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 237,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 335
},
{
"end_pos": 350,
"label_type": "药物",
"overlap": 0,
"start_pos": 347
},
{
"end_pos": 379,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 374
},
{
"end_pos": 430,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 421
},
{
"end_pos": 436,
"label_type": "药物",
"overlap": 0,
"start_pos": 433
},
{
"end_pos": 441,
"label_type": "药物",
"overlap": 0,
"start_pos": 437
},
{
"end_pos": 446,
"label_type": "药物",
"overlap": 0,
"start_pos": 443
},
{
"end_pos": 474,
"label_type": "药物",
"overlap": 0,
"start_pos": 470
},
{
"end_pos": 487,
"label_type": "药物",
"overlap": 0,
"start_pos": 484
},
{
"end_pos": 526,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 525
},
{
"end_pos": 555,
"label_type": "药物",
"overlap": 0,
"start_pos": 552
},
{
"end_pos": 615,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 596
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，2009年12月底出现黑便，，于当地行胃镜检查并行病理检查示: 胃体中下部溃疡， 病理示中分化腺癌， 无腹胀、泛酸、嗳气、恶心、呕吐、 无头晕、 心悸、乏力等症， 2010年1月13日于我院胃胰科行胃癌根治术， 2010年1月18日，我院病理：切缘未见癌， 胃体可见3X2X1CM3溃疡型肿物， 镜上为中分化腺癌侵及胃壁全层至浆膜层，网膜未见癌， 肝总动脉旁（0/1)、 胃大弯（0/1)淋巴结未见癌， 贲门左(3/3)、 胃小弯(8/9)、幽门上（2/2)淋巴结可见腺癌转移，，免疫组化：CEA(+)、 P53(+)、 PR(-)、 ER-B(+)、 ER(+++)、 共计，LN: 13/16转移， 术后于2010年2月-2010年8月行术后化疗6程， 具体用药为艾素100MG 静点+ 希罗达1500MG BID PO，2014年6月初出现右侧下上肢活动受限， 7月份症状逐渐加重， 7月10日就诊于*****， ，行MRI检查提示：胃癌术后多发脑转移， 行甘露醇及地塞米松、 洛赛克治疗后效果不佳。遂于我院就诊，2014-8-5行奥沙利铂150MG D1+ 替吉奥 50MG BID D1-14化疗一程，2014-08-18开始行三维适形全脑放疗，剂量30GY/10F。2014-09-19始行替吉奥 50MG BID D1-14单药化疗一程。本次为行上一程化疗收入我科， 我科以“胃癌术后脑转移 RTXNXM1 IV期”收入， 入科以来， 精神饮食尚可， 无恶心、 呕吐,二便正常，体重无明显减低。 | |
[
{
"end_pos": 9,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 48,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 51,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 61,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 138,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 229,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 243,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 293,
"label_type": "药物",
"overlap": 0,
"start_pos": 289
},
{
"end_pos": 306,
"label_type": "药物",
"overlap": 0,
"start_pos": 302
},
{
"end_pos": 314,
"label_type": "药物",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 336,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 335
},
{
"end_pos": 402,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 401
},
{
"end_pos": 405,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 404
},
{
"end_pos": 436,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 431
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因低位直肠癌于2014-08-27在全麻上行直肠癌根治术（DIXON）。，术中探查见：腹腔内无腹水，腹膜无转移，肝脏未触及转移结节，肿瘤位于腹膜返折处，手术顺利，术后给予抑酸、抗感染、营养支持等治疗。术后病理（201413291），：（直肠）腺癌(中度分化),浸润溃疡型,体积7.5*4.5*2CM,部分侵穿纤维膜达脂肪组织，距底部切除面甚近，局部侵达浆膜，浆膜面未查见癌。 双端切线及另送“近切线”、“远切线”未查见癌。 呈一站（6/10个）淋巴结癌转移。 中央组（7个）淋巴结未查见癌。 ，癌组织免疫组化染色示：TS（-）、SYN（-）。术后给予3周期化疗，，方案为：奥沙利铂200MG D1，亚叶酸钙0.3G+替加氟1.0G D2-D6，同时给与升白细胞、护肝、止吐、免疫增强治疗，过程顺利，自下次出院以来，患者一般情况保持良好；无发热，无恶心、呕吐，无反酸、嗳气，无明显进食不适；未现明显腹痛、腹胀。现患者为行复查并辅助化疗而再来我院就诊，门诊以“直肠癌术后”收入院。 患者精神好，食欲、饮食好，睡眠可；肛门排气排便存在。无体重变化。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 48,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 95,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 164,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 158
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 190,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 203,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 195
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 229,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 221
},
{
"end_pos": 249,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 242
},
{
"end_pos": 267,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 274,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 431,
"label_type": "药物",
"overlap": 0,
"start_pos": 429
},
{
"end_pos": 447,
"label_type": "药物",
"overlap": 0,
"start_pos": 443
},
{
"end_pos": 473,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 472
},
{
"end_pos": 476,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 475
},
{
"end_pos": 503,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 500
},
{
"end_pos": 523,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 522
},
{
"end_pos": 526,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 525
},
{
"end_pos": 546,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 541
},
{
"end_pos": 554,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 550
},
{
"end_pos": 576,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 575
},
{
"end_pos": 579,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 578
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前6月余于我院诊为胃窦癌，于2016年02月26日在全麻上行腹腔镜上根治性远端胃切除术，术顺，，病理：（远端胃），：胃窦溃疡型低黏附性癌（印戒细胞癌为主，部分为未分化癌及黏液腺癌），侵犯脉管及神经组织，脉管内见癌栓，侵出浆膜层。手术标本下切端、上切端及另送（下切端）均未见癌浸润。找到小弯侧淋巴结0/8个，幽门下淋巴结0/1个，幽门上淋巴结4/9个，另送（第1组）淋巴结0/1个,（第7组）淋巴结0/1个，（第8组）淋巴结0/6个，（第9组）淋巴结0/1个，见癌转移。另送（第12组淋巴结）镜上为脂肪、纤维及脉管组织。（小肠），：送检小肠组织，未见癌浸润。，免疫组化染色结果：KI67（70%阳性），P53（-），P170（+++），GSTπ（-），EGFR（+++），5-FU（+），HER-2（-）。术后予制酸、营养支持等治疗好转后出院。术后予2016-04-12、2016.5.6、2016.5.30、2016.6.23、2016.8.9行“洛铂D150MGIVGTT+卡培他滨D2-141500MGPOBID”化疗6次，辅以保肝、保胃、止吐抗肿瘤治疗。此次入院前2天因无明显诱因出现中下腹绞痛，伴恶心，无呕吐，无畏冷、寒战，无腹胀、腹痛等其他不适，求诊我科，门诊拟胃窦癌术后化疗后，腹痛待查收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 31,
"label_type": "手术",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 47,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 52,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 90,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 96,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 94
},
{
"end_pos": 115,
"label_type": "药物",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 118,
"label_type": "药物",
"overlap": 0,
"start_pos": 116
},
{
"end_pos": 131,
"label_type": "药物",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 137,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 182,
"label_type": "手术",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 210,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 213
},
{
"end_pos": 225,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 230
},
{
"end_pos": 237,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 245,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 243
},
{
"end_pos": 267,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 278,
"label_type": "药物",
"overlap": 0,
"start_pos": 275
},
{
"end_pos": 281,
"label_type": "药物",
"overlap": 0,
"start_pos": 279
},
{
"end_pos": 294,
"label_type": "药物",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 300,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 299
},
{
"end_pos": 310,
"label_type": "药物",
"overlap": 0,
"start_pos": 307
},
{
"end_pos": 313,
"label_type": "药物",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 322,
"label_type": "药物",
"overlap": 0,
"start_pos": 320
},
{
"end_pos": 364,
"label_type": "药物",
"overlap": 0,
"start_pos": 361
},
{
"end_pos": 367,
"label_type": "药物",
"overlap": 0,
"start_pos": 365
},
{
"end_pos": 378,
"label_type": "药物",
"overlap": 0,
"start_pos": 374
},
{
"end_pos": 441,
"label_type": "药物",
"overlap": 0,
"start_pos": 437
},
{
"end_pos": 454,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 453
},
{
"end_pos": 457,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 456
},
{
"end_pos": 466,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 465
},
{
"end_pos": 477,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 476
},
{
"end_pos": 516,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 501
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2015年5月26日在我院行腹腔镜检查+卵巢肿瘤活检术。，术后病理学检查报告：(左卵巢)破碎卵巢组织见部分异型性腺体和分化较低的片巢状细胞，局灶伴鳞状下皮化生，符合恶性肿瘤，考虑为腺癌。于5月30日给予TP方案化疗（紫杉醇（特素）240MG静脉滴注，顺铂90MG腹腔灌注）。于７月３日在全麻上经腹行全子宫切除术+两侧附件切除术+大网膜部分切除术+阑尾切除术。，术后病检示：1、（左卵巢）中-低分化浆液性乳头状腺癌，同侧输卵管未见癌累及。右卵巢见癌转移，右输卵管、子宫未见癌转移。阑尾未见癌转移。大网膜见癌转移。2、子宫平滑肌瘤。于７月１３日行紫杉醇（泰素）240MG静脉滴注＋顺铂90MG灌腹，8月14日行紫杉醇（泰素）240MG+顺铂100MG静脉滴注化疗，9月19日、10月21日、11月19日、12月19日行紫杉醇（泰素）240MG+奥沙利铂200MG化疗。化疗过程中，患者有恶心、呕吐、脱发等症状，化疗结束后缓解。入院前20天，患者于我科门诊复查，门诊给予“华蟾素片”治疗，自诉用药后患者感腹痛、腹胀，尚能忍受，无腹泻、恶心、呕吐等。因腹痛持续，患者遂于今日来院。门诊以“第六次化疗后、卵巢浆液性乳头状腺癌IIIC期”收住入院。\U0004 患者本次发病以来，食欲正常， 神志清醒，精神尚可，睡眠尚可，大便正常，小便正常，体重无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 51,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 62,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 78,
"label_type": "药物",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 86,
"label_type": "药物",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 154,
"label_type": "手术",
"overlap": 0,
"start_pos": 116
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 176,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 189,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 196,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 194
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 197
},
{
"end_pos": 203,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 201
},
{
"end_pos": 210,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 204
},
{
"end_pos": 243,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 249,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 261,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 257
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，2016.1.29患者以“阴道不规则出血半年”为主诉首次入院，我院病理科会诊为浸润性低分化鳞状细胞癌，诊断宫颈鳞癌IIB期，，术前予TP化疗2周期：紫杉醇480MG、顺铂220MG，检查无手术禁忌症，2016-03-18在全麻上行III型全子宫及及两附件两附件切除及盆腔淋巴结清扫术及腹主动脉旁淋巴结活检术，术顺，，术后病理回报：盆腔及腹主动脉淋巴结未见转移癌。宫旁及子宫动脉未见癌。全子宫及两附件示宫颈及宫体上段肌层（均大于1/2肌层）中见异型细胞呈小巢团状排列，病变诊断为低分化癌，符合腺鳞癌，可见脉管癌栓，阴道穹窿可见个别散在的癌细胞，检查现为术后放疗入院。自起病以来，患者精神、睡眠可，食欲如常，大小便正常，体重无上降。 | |
[
{
"end_pos": 18,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 90,
"label_type": "手术",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 118,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 215,
"label_type": "药物",
"overlap": 0,
"start_pos": 211
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。2014-08因食纳差，检查发现下腹包块，2014-09-03在全麻上行剖腹探查术，术中见肿瘤位于十二指肠，约10*11*10CM，质硬，与周围组织粘连致密无法切除，行胃空肠吻合术（未见手术记录）。术后病理：（十二指肠肿物）梭形细胞肿瘤，瘤细胞细胞增生活跃，核分裂多见，大于10/10HPF，CD117(3+),CD34(-),DOG-1(3+),CK(-),S-100(-),SMA(-),KI67(+25%)。术后口服伊马替尼（**产）治疗至今。患者目前乏力，近1月出现黑便，一般情况尚可。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 102,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 121,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 246,
"label_type": "药物",
"overlap": 0,
"start_pos": 242
},
{
"end_pos": 260,
"label_type": "药物",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 274,
"label_type": "药物",
"overlap": 0,
"start_pos": 271
},
{
"end_pos": 306,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 305
},
{
"end_pos": 308,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 307
},
{
"end_pos": 339,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 334
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，者约于1个月前因“结肠恶性肿瘤”于2013-04-28日在全麻上行左半结肠切除术。手术过程顺利，术后给予抗感染及营养支持治疗，患者恢复好。，术后病理：4976.2013 结肠腺癌（中低分化），浸润溃疡型，面积5.5*5.5CM，局部粘液腺癌图像，侵达浆膜脂肪组织。双端切线未查见癌，呈肠壁一站（2/8个）淋巴癌转移。肠壁二站（2个）、中间组（4个）淋巴结未查见癌。，免疫组化染色示癌组织：ERCC1(+),TS（-）。术后分期 PT4N1M0 III期，术后给予化疗治疗，，方案为：奥沙利铂200MG D1+右亚叶酸钙50 MGD2-6 +氟尿苷1000MG D2-6 静滴。 院外期间，患者无发热，无腹痛腹胀不适，大便通畅。现患者为行复查化疗来我科就诊，以“结肠癌术后”收入院。 病人自下次出院以来，神志清，精神可，饮食可，大、小便正常，体重未见明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 37,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 51,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 95,
"label_type": "手术",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 117,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 124
},
{
"end_pos": 164,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 317,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 316
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2015-09-15因“腹痛伴大便性状习惯改变1月”就诊于我院结直肠科，外院肠镜检查提示结肠肝曲环周肿物，肠镜不能通过，活检病理提示腺癌，遂2015-09-18行全麻上“左半结肠切除术”，过程顺利，，术后病理示：镜检为中分化腺癌，癌组织浸润至肠壁浆膜上层；未见明确脉管内癌栓及神经束侵犯；各切缘未见癌；淋巴结2/10见腺癌转移，，免疫组化：ER（-），ERCC1（+），MSH2（+），MSH6（+），MLH1（+），PMS2（+），KI67（40%+），，分期为：PT3N1BM0IIIB期，术后恢复可。2015-10-15于我科行第1程XELOX方案术后辅助化疗，过程顺利，现患者为行进一步治疗入我科。患者3周来，无发热，胃纳可，睡眠一般，大小便正常，体重无明显上降。 | |
[
{
"end_pos": 27,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 20
},
{
"end_pos": 30,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 64,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 78,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 87,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 138,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 136
},
{
"end_pos": 151,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 179,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 177
},
{
"end_pos": 221,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 212
},
{
"end_pos": 234,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 223
},
{
"end_pos": 245,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 267,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 270,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 269
},
{
"end_pos": 273,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 276,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 275
},
{
"end_pos": 311,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 308
},
{
"end_pos": 346,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 342
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前半个月前我院行胃镜检查提示：食管炎（A级），贲门息肉样隆起，共双枚，大小分别为1.0CM、1.5CM，慢性萎缩性胃炎，十二指肠球部溃疡（S2期），十二指肠球部炎症。，胃镜病理：（十二指肠降部）间质中量慢性炎症细胞及少量急性炎症细胞浸润，灶性腺体呈腺瘤样增生。（贲门）腺下皮轻度肠化，其上见胃固有腺，间质大量急、慢性炎症细胞浸润。，肠镜检查示：结肠多发息肉，直径0.6CM-1CM。予内镜上切除部分小息肉。，病理：（肝曲）肠管状腺瘤，伴腺下皮低级别下皮内瘤变，（横结肠）肠管状腺瘤，伴腺下皮低级别下皮内瘤变（中度不典型增生）。无腹痛、腹胀、腹泻、呕血、排黑便、排血便、里急后重，无恶心、呕吐，无反酸、嗳气、胸骨后烧灼感，无消瘦、食欲减退等。今为求进一步诊治求诊我院，门诊拟“胃肠息肉”收住院。近半个月以来，精神、睡眠、食欲尚可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 25,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 30,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 27
},
{
"end_pos": 68,
"label_type": "手术",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 147,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 111
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 318,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 343,
"label_type": "药物",
"overlap": 0,
"start_pos": 339
},
{
"end_pos": 359,
"label_type": "药物",
"overlap": 0,
"start_pos": 355
},
{
"end_pos": 373,
"label_type": "药物",
"overlap": 0,
"start_pos": 369
},
{
"end_pos": 386,
"label_type": "药物",
"overlap": 0,
"start_pos": 383
},
{
"end_pos": 417,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 416
},
{
"end_pos": 473,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 466
},
{
"end_pos": 498,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 497
},
{
"end_pos": 501,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 500
},
{
"end_pos": 504,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 503
},
{
"end_pos": 539,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 531
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前39个月因反复左上腹痛于我院行腹部B超示：回盲部壁增厚,癌可能。并于2010.11.1于我院肿瘤外科在全麻上行左半结肠切除术,盲肠部可及一大约3CM*4CM肿物，侵及浆膜层。术后病理（201026573），示：(左半结肠)大肠回盲部结外粘膜相关淋巴组织边缘区B细胞淋巴瘤(MALT),侵犯浆膜层，手术标本双切端未见肿瘤。找到肠周淋巴结1/19个见淋巴瘤细胞浸润。，免疫组化：CD3（-），CD5（-），CD10（-），CD20（+++），CD21（-），CD23（-），CD30（-），CYCLIND1（-），KI67（10%），BCL-2（+++），CD56（-）。术后恢复可，切口II/甲愈合。术后进一步查胸部+全腹CT未见明显复发转移征象，术后先后予CHOP（环磷酰胺1100MGIV，D1+表柔比星90MGIV，D1+长春新碱2MG，IV，D1+泼尼松10MGTID，D1-D14）3周方案全身化疗4周期，辅以保肝、止吐、调节免疫力等处理，化疗过程较顺利。最后一次化疗2011年1月27日。此后定期（3个月）复查胸部+全腹CT增强未见复发转移征象，血清β2微球蛋白阴性。今无腹痛、腹胀、腹泻，无恶心、呕吐等不适，今为求复查再次就诊我院，门诊拟回盲部淋巴瘤术后收住院。本次发病以来，精神、睡眠、食欲可，大小便如常，体重无骤变。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 49,
"label_type": "手术",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 78,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 65
},
{
"end_pos": 128,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 123
},
{
"end_pos": 139,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 144
},
{
"end_pos": 161,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 191,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 183
},
{
"end_pos": 204,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 209
},
{
"end_pos": 296,
"label_type": "药物",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 299,
"label_type": "药物",
"overlap": 0,
"start_pos": 297
},
{
"end_pos": 314,
"label_type": "药物",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 362,
"label_type": "药物",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 372,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 370
},
{
"end_pos": 391,
"label_type": "药物",
"overlap": 0,
"start_pos": 388
},
{
"end_pos": 402,
"label_type": "药物",
"overlap": 0,
"start_pos": 398
},
{
"end_pos": 417,
"label_type": "药物",
"overlap": 0,
"start_pos": 413
},
{
"end_pos": 459,
"label_type": "药物",
"overlap": 0,
"start_pos": 456
},
{
"end_pos": 470,
"label_type": "药物",
"overlap": 0,
"start_pos": 466
},
{
"end_pos": 485,
"label_type": "药物",
"overlap": 0,
"start_pos": 481
},
{
"end_pos": 507,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 506
},
{
"end_pos": 540,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 536
},
{
"end_pos": 562,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 561
},
{
"end_pos": 565,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 564
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前3月余前于我院诊为胃癌，于2014-12-12在全麻上行腹腔镜上根治性远端胃大部切除术，术顺。术后病理示（胃大部），：胃体大弯侧溃疡型低分化腺癌，侵及浆膜层，侵犯神经，手术标本下、上双切端及另送（下切端）、（上切端）均未见癌浸润。找到小弯淋巴结0/10个，大弯淋巴结2/8个，幽门下淋巴结0/2个，幽门上淋巴结0/2个，及另送的（第一组）淋巴结0/1个，（第七组）淋巴结0/5个，（第八组）淋巴结0/1个，（第十二组）淋巴结0/3个，见癌转移。（第九组），：送检脂肪、纤维及神经组织。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。患者于2015-01-05行“奥沙利铂（齐沙）200MGIVGTT+替吉奥60MGPOD1-14。”化疗方案治疗1周期，辅以止吐、制酸、保肝等对症支持治疗，患者口服替吉奥时出现皮肤瘙痒、皮疹等不适，2015-01-24行“替加氟3.6G泵入+奥沙利铂130MGIVGTT+亚叶酸钙300MGIVGTT”方案化疗，2015-02-11，2015-02-28予“替加氟3.6G泵入+奥沙利铂130MGIVGTT+亚叶酸钙300MGIVGTT”方案化疗辅以止吐、保肝、制酸等处理。今为行第5周期化疗治疗，再次就诊我院，门诊拟胃癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 21,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 71,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 73,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 97,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 113,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 117,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 114
},
{
"end_pos": 129,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 135,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 166,
"label_type": "手术",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 172,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 176
},
{
"end_pos": 182,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 195,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 189
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 331,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 338,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 359,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 353
},
{
"end_pos": 382,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 376
},
{
"end_pos": 417,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 411
},
{
"end_pos": 673,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 667
},
{
"end_pos": 680,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 674
},
{
"end_pos": 687,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 681
},
{
"end_pos": 763,
"label_type": "药物",
"overlap": 0,
"start_pos": 759
},
{
"end_pos": 776,
"label_type": "药物",
"overlap": 0,
"start_pos": 772
},
{
"end_pos": 789,
"label_type": "药物",
"overlap": 0,
"start_pos": 786
},
{
"end_pos": 820,
"label_type": "药物",
"overlap": 0,
"start_pos": 816
},
{
"end_pos": 837,
"label_type": "药物",
"overlap": 0,
"start_pos": 833
},
{
"end_pos": 854,
"label_type": "药物",
"overlap": 0,
"start_pos": 851
},
{
"end_pos": 887,
"label_type": "药物",
"overlap": 0,
"start_pos": 883
},
{
"end_pos": 900,
"label_type": "药物",
"overlap": 0,
"start_pos": 896
},
{
"end_pos": 913,
"label_type": "药物",
"overlap": 0,
"start_pos": 910
},
{
"end_pos": 953,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 949
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2014年3月无明显诱因上出现中下腹疼痛，较剧烈，每次持续2-3分钟，不伴放射痛，有反酸嗳气，患者食欲欠佳，进食油腻食物后即感恶心，无腹胀腹泻，无呕血黑便。于2014-4-1行PET-CT考虑为胃窦部MT伴胃周淋巴结转移；脂肪肝；肝左后叶上段及两肾囊肿；左肾小结石；2014-04-02在我院全麻上行胃癌根治术，毕II式远端胃。术中见腹腔无腹水，肝脏、腹盆腔大网膜无异常。胃窦部小弯侧直径2CM增厚区，未浸润浆膜，胃周围可见肝动脉旁3CM肿瘤结节，淋巴结明显肿大。，病理：(远端胃)下皮性恶性肿瘤，部分区为神经内分泌癌(G3，约占肿瘤体积40%)；部分为肉瘤样癌(约占肿瘤体积40%)；部分为管状腺癌，分化II级(LAUREN分型肠型，约占肿瘤组织20%)。癌组织浸润胃壁肌层。双切缘未见癌累及。检出大弯侧淋巴结8枚，均未见癌转移(0/8)；检出小弯侧淋巴结19枚，其中5枚见癌转移(5/19)，另见癌结节1枚；检出幽门上淋巴结12枚，其中3枚见癌转移(3/12)。免疫组化(2014-N3491)，:TP(60%+),TS(20%+),B-TUBULIN(30%+),KI67(60%+),TOPII-A(40%+),ERCC-1(-),C-MET(-),HER-2(0),CK广(神经内分泌癌及肠型腺癌区域100%++,肉瘤样癌区域约10%+),SYN(30%++),CHG(30%++),CD56(部分+)。 手术过程顺利。术后恢复良好。患者术后分期PT2N3M0 IIIA期，有术后辅助化疗指征，考虑患者术后病理提示部分神经内分泌癌、部分肉瘤样癌、部分管状腺癌，拟三药联合方案，于2014.5.12、2014.6.2、2014.6.23、2014.7.15行第1-4次EOX方案术后辅助化疗，，计划用药：表柔比星 50MG/M2，奥沙利铂 130MG/M2，希罗达 1000MG/M2 BID D1-14，，计算用药：表柔比星 76.605MG D1，奥沙利铂 199.173MG D1，希罗达 1532.1MG/M2 BID D1-14，，实际用药：表柔比星100MG D1，奥沙利铂 150MG D1，希罗达 1500MG BID D1-14 Q3W，期间于2014.7.15复查腹部CT未见明确复发转移灶。患者化疗耐受可，今日为行第5次辅助化疗治疗入院。患者患病以来，精神可，夜眠可，二便无殊，近期体重稳定。 | |
[
{
"end_pos": 17,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 48,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 62,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 67,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 66
},
{
"end_pos": 71,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 73,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 131,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 138,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 136
},
{
"end_pos": 142,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 185,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 207,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 206
},
{
"end_pos": 226,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 236,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 242,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 274,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 269
},
{
"end_pos": 285,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 279
},
{
"end_pos": 296,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 290
},
{
"end_pos": 434,
"label_type": "药物",
"overlap": 0,
"start_pos": 430
},
{
"end_pos": 450,
"label_type": "药物",
"overlap": 0,
"start_pos": 447
},
{
"end_pos": 491,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 486
},
{
"end_pos": 515,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 514
},
{
"end_pos": 518,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 517
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前6月余于我院诊为胃窦癌，于2016-6-14在全麻上行腹腔镜上根治性远端胃大部切除术。，术中见：腹腔镜探查见腹腔内无明显腹水，盆腔、腹壁、大网膜未见明显转移结节，肝脏质地大小正常，未见明显肿物，胆囊无肿大。胃窦幽门管可见病灶，侵及浆膜层，侵及部分肝脏，侵及部分胰腺及横结肠系膜，周围可见大量肿大淋巴结，最大约1.5×1㎝，考虑为“胃窦癌伴出血伴肝脏、胰腺受侵”。术后病理（201620266）示（远端胃），：胃窦浸润型管状腺癌II-III级，侵出浆膜层，侵犯肝被膜至肝实质。手术标本下、上切端及另送（下切端）均未见癌浸润。找到小弯淋巴结0/7个，幽门下淋巴结1/4个，幽门上淋巴结2/8个，见癌转移。，免疫组化：KI67（50%+），CK8（++），CK7（-），CK20（++），CD56（-），HER-2（-），术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。术后分别于2016-09-04、2016-10-12、2016-11-07行乐沙定150MGIVGTTD1+替吉奥40MGPOBIDD1-14方案化疗，此次为行第4次化疗就诊我院，门诊拟胃窦癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 26,
"label_type": "手术",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 35,
"label_type": "手术",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 48,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 60,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 68,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 216,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 215
},
{
"end_pos": 219,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 218
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2016-10-12在全麻上行\"胃癌根治术\"（远端胃切除术），，术后病理回报:“（胃大体）镜检为胃低粘附性癌，符合低分化腺癌，LAUREN，分型：弥漫型，癌组织浸润至胃壁浆膜上层，可见脉管内癌栓及神经束侵犯；网膜组织未见癌。淋巴结46枚，4枚见癌。（远、近切缘）未见癌”。2016-11-11，2016-12-05，2016-12-28已行SOX方案化疗3程，现为行上一程术后辅助化疗收入我科。患者目前无恶心、呕吐，无腹泻、腹胀，精神尚可，食欲一般，大小便正常，身体减轻4KG。 | |
[
{
"end_pos": 22,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 41,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 46,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 68,
"label_type": "手术",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 79,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 117,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 175,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 173
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2015年初患者出现呕吐、呕吐血性胃内容物，，外院查胃镜示：胃窦癌伴胃潴留，考虑胃癌，于2015-02-09于外院行“胃癌根治术”，病理提示低分化腺癌，，术后病理诊断：PT4N1M0（我院会诊病理切片示（胃窦）镜检为低分化腺癌，浸润胃壁全层至浆膜外脂肪组织。送检双切缘未见癌。送检癌结节一枚，淋巴结4枚，1/4见癌转移。）。术后于我院复查CT示未见复发转移。于2015-03及04月、2015-5-4给予SOX方案化疗3程顺利，无不适。今为求进一步诊治来我院。患者发病以来,有呕吐等症状。精神不佳,饮食睡眠佳,大小便正常，体重无减轻。 | |
[
{
"end_pos": 32,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 72,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 80,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 78
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 96,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 94
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 117,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 112
},
{
"end_pos": 125,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 166,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 156
},
{
"end_pos": 178,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 188,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 242,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 257,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 339,
"label_type": "药物",
"overlap": 0,
"start_pos": 336
},
{
"end_pos": 358,
"label_type": "药物",
"overlap": 0,
"start_pos": 354
},
{
"end_pos": 388,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 387
},
{
"end_pos": 433,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 425
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1月余于我院诊为肝曲结肠粘液腺癌侵犯十二指肠及肝门区，于2016-08-03在全麻上行剖腹探查+胃空肠吻合+升结肠-横结肠侧侧吻合术，，术中见:腹腔内无明显腹水，肝脏表面光滑，盆腔、肠系膜、网膜表面未见明显结节，升结肠肠管略扩张，结肠肝曲可触及一大小约8*7CM肿物，质硬，侵出浆膜层，并向后侵犯包绕十二指肠降部、水平部，向下侵犯肝十二指肠韧带上方，肿物部分与后腹膜粘连致密固定无法分离。遂行下术，术顺，术后予补液、抗感染、营养支持等治疗。，术后病理：(左结肠动脉旁淋巴结)，：送检淋巴结1个见粘液腺癌转移，结合免疫组化结果，考虑消化系统来源。，免疫组化结果：CK7（-），CK20（+++），PAX-8（-），CDX2（+++）。并于2016-08-24予“乐沙定100MGIVGTTQDD1+卡培他滨1500MGPOBID×14天”方案行第1周期化疗，辅以保胃、保护粘膜、止吐及营养支持处理。今为行上一周期化疗，就诊我院门诊，门诊拟“升结肠癌术后化疗”收住入院，病程中精神、饮食、睡眠尚可，大小便正常，体重较前上降2KG。 | |
[
{
"end_pos": 10,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 42,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 73,
"label_type": "手术",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 101,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 107,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 156,
"label_type": "手术",
"overlap": 0,
"start_pos": 149
},
{
"end_pos": 190,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 189
},
{
"end_pos": 226,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 196
},
{
"end_pos": 234,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 233
},
{
"end_pos": 271,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 269
},
{
"end_pos": 282,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 292,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 290
},
{
"end_pos": 303,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 297
},
{
"end_pos": 313,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 311
},
{
"end_pos": 324,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 318
},
{
"end_pos": 336,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 334
},
{
"end_pos": 347,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 357,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 355
},
{
"end_pos": 368,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 362
},
{
"end_pos": 391,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 385
},
{
"end_pos": 401,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 399
},
{
"end_pos": 412,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 406
},
{
"end_pos": 422,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 420
},
{
"end_pos": 435,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 427
},
{
"end_pos": 554,
"label_type": "药物",
"overlap": 0,
"start_pos": 551
},
{
"end_pos": 573,
"label_type": "药物",
"overlap": 0,
"start_pos": 570
},
{
"end_pos": 610,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 609
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“反复餐后腹胀、恶心1月余”于2015-07-03入住我院，外院未经提示胃癌，于2015-07-16在全麻上行胃癌姑息切除术（远端胃大切），，术中探查见：小网膜囊可见少量硬结，盆底、横结肠、肝脏、胰腺、脾脏等未见种植转移结节，肿物位于胃窦，大小约6*8CM，突破浆膜，侵犯周围结缔组织，遂行胃癌姑息切除术，术后预防感染支持对症等处理，恢复好，切口甲级愈合。术后病理示1（胃大体）镜检为中至低分化腺癌，部分为粘液腺癌（LAUREN，分型：混合型），癌组织浸润至胃壁浆膜层；可见脉管内癌栓及神经束侵犯；网膜组织中见淋巴结2枚，2/2见腺癌转移。2（第1组淋巴结）5枚，4/5见腺癌转移。3（第3组淋巴结）4枚，3/4见腺癌转移。4（第4组淋巴结）11枚，7/11见腺癌转移。5（第5组淋巴结）3枚，3/3见腺癌转移。6（第6组淋巴结）镜上为脂肪结缔组织，未见癌。7（第7组淋巴结）3枚，3/3见腺癌转移。8（第8组淋巴结）2枚，2/2见腺癌转移。9（第12A组淋巴结）镜上为脂肪结缔组织，未见癌。10（近切缘）未见癌。11（远切缘）未见癌。，免疫组化：VEGF（+），HER-2（0）。，原位杂交：EBERS（-）。术后于2015-09-17、2015-10-15、2015-11-12予以SOX（S-1 60MG，BID×D1-14+OXA190MG×D1）方案化疗3程。今为求进一步诊治来我院。患者发病以来,无腹痛、恶心、呕吐、反酸、嗳气。精神佳,饮食睡眠佳,大小便正常，体重无减轻。 | |
[
{
"end_pos": 15,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 33,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 41,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 76,
"label_type": "手术",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 84,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 88,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 109,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 137,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 206,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 205
},
{
"end_pos": 224,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 209
},
{
"end_pos": 276,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 271
},
{
"end_pos": 287,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 299,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 310,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 304
},
{
"end_pos": 325,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 317
},
{
"end_pos": 340,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 330
},
{
"end_pos": 354,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 369,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 393,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 392
},
{
"end_pos": 430,
"label_type": "药物",
"overlap": 0,
"start_pos": 426
},
{
"end_pos": 441,
"label_type": "药物",
"overlap": 0,
"start_pos": 439
},
{
"end_pos": 455,
"label_type": "药物",
"overlap": 0,
"start_pos": 453
},
{
"end_pos": 480,
"label_type": "药物",
"overlap": 0,
"start_pos": 477
},
{
"end_pos": 532,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 528
},
{
"end_pos": 536,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 533
},
{
"end_pos": 565,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 559
},
{
"end_pos": 579,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 577
},
{
"end_pos": 599,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 593
},
{
"end_pos": 606,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 602
},
{
"end_pos": 639,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 635
},
{
"end_pos": 657,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 651
},
{
"end_pos": 670,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 667
},
{
"end_pos": 685,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 680
},
{
"end_pos": 743,
"label_type": "药物",
"overlap": 0,
"start_pos": 739
},
{
"end_pos": 746,
"label_type": "药物",
"overlap": 0,
"start_pos": 744
},
{
"end_pos": 761,
"label_type": "药物",
"overlap": 0,
"start_pos": 757
},
{
"end_pos": 776,
"label_type": "药物",
"overlap": 0,
"start_pos": 773
},
{
"end_pos": 818,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 808
},
{
"end_pos": 828,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 821
},
{
"end_pos": 831,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 830
},
{
"end_pos": 856,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 852
},
{
"end_pos": 868,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 864
},
{
"end_pos": 893,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 892
},
{
"end_pos": 913,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 905
},
{
"end_pos": 939,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 933
},
{
"end_pos": 948,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 940
},
{
"end_pos": 952,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 949
},
{
"end_pos": 968,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 963
},
{
"end_pos": 1018,
"label_type": "手术",
"overlap": 0,
"start_pos": 1004
},
{
"end_pos": 1026,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 1025
},
{
"end_pos": 1091,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 1090
},
{
"end_pos": 1108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 1107
},
{
"end_pos": 1136,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 1129
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前20个月因“中下腹闷痛”就诊于我院，查胃镜提示胃窦溃疡，恶性待排，住胸外科于2012.05.21在全麻上行根治性远端胃大部切除＋毕Ｉ式吻合术，术中探查未见腹水，盆底、肝脏表面无转移性结节，肿瘤位于胃窦小弯侧，呈溃疡型，范围约4CMX3CM，侵及浆膜，另见小弯侧胃壁3枚米粒大小结节，，切除结节送术中冰冻示：平滑肌和小淋巴结2个，送检淋巴结呈反应性增生。手术顺利，术后病理（201214740），：(胃)，：胃窦小弯侧溃疡型管状腺癌II级，侵及浆膜层，侵犯神经组织，脉管内见癌栓。手术标本下、上切端及另送（下切端）均未见癌浸润。找到小弯淋巴结1/14个、大弯淋巴结1/18个、幽门下淋巴结1/2个、幽门上淋巴结1/9个及另送(贲门右)淋巴结0/3个、(胃右动脉旁)淋巴结0/7个、(脾动脉旁)淋巴结0/2个、(肝总动脉旁)淋巴结0/4个见癌转移，（201214606），：(胃壁结节)送检少量平滑肌组织及淋巴结二个，淋巴结反应性增生。术后予“5-FU7500MG泵入+CF300MG静滴D1-5+顺铂30MG静滴D1-5Q3W”化疗3周期及口服希罗达化疗2周期（具体不详），末次化疗时间2012.10。术后定期复查未见肿瘤复发转移。12，周前复查腹部B超：肝左叶实质性占位性病变，大小约27MM×26MM，，下消化道钡餐：吻合口区钡剂通过顺畅，两肺纹理增多增粗。遂就诊我科，查下腹部，CT：1、肝右内叶占位性病变，与2012-05-15旧片对比为新增病灶，考虑肝转移瘤，另肝内数个小囊肿，2、两肾多发囊肿，两肾小结石或钙化；CEA24.8NG/ML；CA199149.1U/ML。于2013.11.2、2013.11.16、2013.11.30予FOLFOX两周方案“奥沙利铂(艾恒)120MG静滴D1+亚叶酸钙300MG静滴D1、2+替加氟3G持续泵入44HD1Q2W”姑息性化疗3周期，过程顺利。后复查腹部CT平扫+，增强：1、胃大部切除术后，残胃充盈欠佳，吻合口区未见明显占位性病变。2、肝右内叶占位性病变，考虑肝转移瘤，与2013-10-31旧片对比较前明显减小，另肝内数个小囊肿。3、所摄入右侧肾下腺内侧肢增粗，部分略呈结节状，转移不能排除。4、两肾多发囊肿；两肾小结石或钙化。CER13.97NG/ML，CA12510.95U/ML。疗效评价为PR。于2013.12.16在基础麻醉上行超声引导上右肝肿块射频消融术，术顺，术后无腹痛、恶心、呕吐等不适。于2013.12.21、2013.01.04予原方案（FOLFOX两周方案）化疗第4、第5周期。目前患者无腹痛、恶心、呕吐，无纳差、乏力，无眼黄、尿黄、皮肤黄，今为进一步诊治，门诊拟“胃癌术后肝转移”收入我科。术后精神、睡眠、食欲尚可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 47,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 45
},
{
"end_pos": 61,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 79,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 74
},
{
"end_pos": 81,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 80
},
{
"end_pos": 95,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 94
},
{
"end_pos": 132,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 128
},
{
"end_pos": 159,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 158
},
{
"end_pos": 204,
"label_type": "手术",
"overlap": 0,
"start_pos": 198
},
{
"end_pos": 253,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 340,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 304
},
{
"end_pos": 501,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 499
},
{
"end_pos": 543,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 542
},
{
"end_pos": 546,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 545
},
{
"end_pos": 550,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 549
},
{
"end_pos": 561,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 560
},
{
"end_pos": 564,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 563
},
{
"end_pos": 608,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 605
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“进食阻挡感1月余”于2017.10.23第1次入住我院，入院后完善相关辅助检查，CT检查示“考虑食管上段贲门CA可能性大，请结合内镜检查；肝多发囊肿；肝内钙化灶”，给予抑酸、保护胃黏膜、抗氧化等对症支持治疗，结合患者病史、胃镜检查、活检病理，诊断贲门腺癌明确，为行手术治疗于2017.10.25由消化科转入胸外1科。转科后完善相关术前检查，排除手术禁忌后，于2017.10.27全麻上行贲门癌根治术，术后病理（2017.10.31，病理号201725281），示：贲门腺癌（中度分化），浸润溃疡型，体积4*3.5*0.6CM，侵达浆膜；双端切线未查见癌；一组（1个）、二组（1个）、三组（4个）、“上段食管旁”（3个）、“贲门周围”（4个）、“胃右动脉旁”（8个）淋巴结未查见癌。，免疫组化染色示：CERBB-2（3+）、SYN（-）、β-TUBULIN-III少数（+）、 RRM1少数（+）、TOPOII多数（+）。术后给予雾化、化痰、抗感染、抑酸、止疼、补液、营养支持等治疗，患者术后恢复良好，经口进食未诉明显不适、病情平稳后出院。 患者自出院以来半流质饮食，偶有进食哽噎感，伴胸骨后烧灼感，无进食疼痛，无嗳气、呃逆，无声音嘶哑、饮食呛咳，无咳嗽、咳痰，无咯血，无胸痛、胸闷，无心悸，无恶心、呕吐，无腹痛、腹泻，今患者为求进一步诊治，再次来我院就诊，拟行全身化疗为主的肿瘤综合治疗，门诊以“贲门癌”收入院。 患者神志清，精神、睡眠好，半流质饮食，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 41,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 82,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 90,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 94
},
{
"end_pos": 111,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 141,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 128
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 160
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 186,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
},
{
"end_pos": 189,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 232,
"label_type": "药物",
"overlap": 0,
"start_pos": 230
},
{
"end_pos": 244,
"label_type": "药物",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 269,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 268
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于1月余前因“进行性吞咽困难伴疼痛半年，加重半个月”就诊我院，查胃镜示“食管癌（距门齿22CM）”，病理（，病理号：201334934）示“食管鳞状细胞癌II级”；，胸腹部CT示：1、食管下段管壁不规则增厚，符合食管癌改变，肿块与气管后壁分界不清，邻近食管下段周围多发肿大淋巴结，下腹部贲门周围一淋巴结轻度增大，2、两上肺少许慢性炎症；两侧胸腔少量积液，3、左侧甲状腺甲状腺占位性病变。考虑肿瘤较大，尚不适手术，予排除化疗禁忌症，于2013.11.15按“顺铂40MGD1-3+安素泰240MGD2”行新辅助化疗，辅以止吐、制酸、保胃、抗过敏等治疗，化疗过程顺利，无诉特殊不适。今为行化疗再次入院。近来，精神、睡眠、饮食一般，大小便如常，体重无明显增减。 | |
[
{
"end_pos": 21,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 31,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 24
},
{
"end_pos": 43,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 51
},
{
"end_pos": 64,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 62
},
{
"end_pos": 79,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 98,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 113,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 133,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 130
},
{
"end_pos": 165,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 173,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 170
},
{
"end_pos": 186,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 238,
"label_type": "药物",
"overlap": 0,
"start_pos": 235
},
{
"end_pos": 241,
"label_type": "药物",
"overlap": 0,
"start_pos": 239
},
{
"end_pos": 257,
"label_type": "药物",
"overlap": 0,
"start_pos": 255
},
{
"end_pos": 280,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 279
},
{
"end_pos": 283,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 282
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前2月于我院查胃镜示：1.食管癌；2.慢性萎缩性胃炎；3.胃角溃疡(S2期)，，胃镜病理：(门齿30CM)，：送检食管粘膜，鳞状下皮高级别下皮内瘤变，部分癌变为鳞状。胸部CT平扫+，增强示：主动脉弓上缘水平至右上上肺静脉水平食管壁不规则明显增厚，考虑食管癌，侵犯外膜可能，伴纵膈及所摄入右锁骨窝区、肝胃间隙多发肿大淋巴结，遂门诊拟食管癌收入院，患者食管中上段鳞癌诊断明确，据其肿瘤分期需行术前新辅助化疗，2016-05-29、2016-06-25予以TP方案“紫杉醇（泰素）210MGIVGTTD2+顺铂40MGIVGTTD1-3”方案化疗，辅以保肝、保胃、抗肿瘤等治疗。发病以来，精神、睡眠可，食欲欠佳，大小便如常，体重减轻6公斤。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 27,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 22
},
{
"end_pos": 41,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 52,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 61,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 85,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 93,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 101
},
{
"end_pos": 124,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 194,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 184
},
{
"end_pos": 203,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 201
},
{
"end_pos": 257,
"label_type": "手术",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 286,
"label_type": "药物",
"overlap": 0,
"start_pos": 283
},
{
"end_pos": 295,
"label_type": "药物",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 309,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 308
},
{
"end_pos": 337,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 335
},
{
"end_pos": 344,
"label_type": "药物",
"overlap": 0,
"start_pos": 341
},
{
"end_pos": 356,
"label_type": "药物",
"overlap": 0,
"start_pos": 350
},
{
"end_pos": 380,
"label_type": "药物",
"overlap": 0,
"start_pos": 376
},
{
"end_pos": 383,
"label_type": "药物",
"overlap": 0,
"start_pos": 381
},
{
"end_pos": 397,
"label_type": "药物",
"overlap": 0,
"start_pos": 394
},
{
"end_pos": 429,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 427
},
{
"end_pos": 439,
"label_type": "药物",
"overlap": 0,
"start_pos": 433
},
{
"end_pos": 462,
"label_type": "药物",
"overlap": 0,
"start_pos": 459
},
{
"end_pos": 466,
"label_type": "药物",
"overlap": 0,
"start_pos": 463
},
{
"end_pos": 476,
"label_type": "药物",
"overlap": 0,
"start_pos": 473
},
{
"end_pos": 500,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 499
},
{
"end_pos": 525,
"label_type": "药物",
"overlap": 0,
"start_pos": 519
},
{
"end_pos": 533,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 531
},
{
"end_pos": 561,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 551
},
{
"end_pos": 587,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 585
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余因胸闷、气促就诊我院，，查全腹部CT提示：1、胃体部大弯、小弯壁不规则增厚，伴肝胃间隙、腹膜后多发淋巴结肿大，网膜增厚，为胃CA侵出浆膜层并网膜种植转移。2、腹腔、盆腔见大量积液。3、脾内类圆形低密度影，可能为转移瘤。4、两附件区多发囊实性病灶，为种植转移可能性大。5、所摄入两肺少许炎症，两侧胸腔少量积液。6、所摄入右房、右室增大。，我院麻醉胃镜：胃体癌慢性萎缩性胃炎。，病理示：（胃体）送检炎性肉芽组织中见多灶粘液湖，其内漂浮个别印戒样细胞，高度可疑癌。2014.03.03行“腹腔置管引流术”，于2014.03.05、2014.04.10予“乐沙定100MG+里葆多40MG”方案化疗，辅以保肝、止吐、补液等处理。过程顺利，无诉不适。03.14予腹腔腔内注射替加氟1G*3天+肿瘤坏死因子200万IU。于2014.05.14按“奥沙利铂(艾恒)150MG静滴D1+里葆多40MGD2”方案化疗，05.19、05.22、05.26予腹腔内注射“肿瘤坏死因子300万IU”。2014.06.23按“紫杉醇（安素泰）180MG+替吉奥60MGBID*14D”方案化疗，辅予止吐、保肝、营养等治疗,于2014.06.25予肿瘤坏死因子300万IU腹腔滴注。此次为化疗再次就诊我院，门诊拟胃体癌伴腹腔种植转移收入院。下次出院以来精神、睡眠、饮食尚可，诉偶有下腹胀痛不适，无发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 8,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 41,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 48,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 47
},
{
"end_pos": 49,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 85,
"label_type": "手术",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 116,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 171,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 150
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 204,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 349,
"label_type": "药物",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 419,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 417
},
{
"end_pos": 426,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 420
},
{
"end_pos": 440,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 438
},
{
"end_pos": 454,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 452
},
{
"end_pos": 466,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 464
},
{
"end_pos": 488,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 484
},
{
"end_pos": 491,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 490
},
{
"end_pos": 499,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 496
},
{
"end_pos": 504,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 500
},
{
"end_pos": 508,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 505
},
{
"end_pos": 523,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 520
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“下腹部隐痛不适3月”于2014年4月就诊我院门诊，行胃镜病理示低分化腺癌，后入住我院胃肠外科于2014年5月6日在全麻上予行根治性远端胃大部切除、毕II式吻合术，术后病理（201406646），：胃窦部腺癌(中、低度分化)，体积4.6*4.5*0.3CM，侵达粘膜上层。双端切线未查见癌。呈四组（2/5个）、五组（1/3个）淋巴结癌转移。六组（4个）、“1、3、7组”（10个）淋巴结未查见癌。（腹膜后）脂肪坏死结节。，免疫组化染色示：ERCC1少量（+）、β-TUBULIN-III少量（+）、TS少量（+）、RRM1（-）、TOPOII多量（+）、CERBB-2（-）、SYN（-）、CGA（-） 。术后患者恢复顺利，并行辅助化疗5周期，，化疗方案为：奥沙利铂200MG D1，希罗达2.0G BID D1-D14；化疗期间患者无明显副反应。末次化疗时间2014年10月8日。患者为行复查于2014年12月入住我科复查，CT：胃贲门癌术后CT所见，建议结合临床，左肺结节灶，较前无明显变化。肝脏多发低密度，符合囊肿CT表现，较前无明显变化，建议复查。复查腹部彩超示；肝内钙化灶，肝囊肿，胆囊息肉，右上腹皮上脂肪层强回声团，考虑脂肪瘤。此次为行复查入院。 目前患者精神及情绪状态可，饮食好，夜间睡眠可，大小便正常，近期无明显体重变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 6
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 28
},
{
"end_pos": 70,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 147
},
{
"end_pos": 160,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 191,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 188
},
{
"end_pos": 220,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 237,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 234
},
{
"end_pos": 239,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 247,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 288,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 264
},
{
"end_pos": 295,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 291
},
{
"end_pos": 319,
"label_type": "药物",
"overlap": 0,
"start_pos": 315
},
{
"end_pos": 332,
"label_type": "药物",
"overlap": 0,
"start_pos": 328
},
{
"end_pos": 346,
"label_type": "药物",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 368,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 365
},
{
"end_pos": 383,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 380
},
{
"end_pos": 466,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 462
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因患“胃癌”于2006-8-9于我院在全麻上予行“姑息性近端胃大部切除、幽门成形术”，，术后病理回示：贲门腺癌（中度分化），浸润溃疡型，面积6*3CM，侵穿浆膜，周围淋巴结未查见癌。术后行6周期化疗，化疗期间病人无明显不适，适应性良好。自出院后，患者每年复查1次，一般情况保持良好,近来感下腹部隐痛不适，无发热、腹泻、腹胀，无反酸、嗳气等不适。３月前患者再次来院复查，查CEA明显增高，为83.96NG/ML,，行胃镜检查示：食管上端近原手术吻合口见菜花样病变，胃食管食管吻合口以远至胃体，见大面积的菜花样隆起，，病理示：（胃体）高级别下皮内瘤变（重度异型增生及原位癌）。考虑胃癌术后复发可能性大，已给予序贯化疗３次，方案为奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1000MG D2-6 静滴。经化疗后CEA指标呈上降趋势，最近１次CEA为50.12NG/ML化疗期间患者消化道反应较重、白细胞降低，均给予对症处理。出院后一般情况良好，进食、大小便恢复正常。现患者为行进一步复查治疗就诊，门诊以“胃癌术后”收入院。 目前患者精神及情绪状态可，食欲、饮食可，夜间睡眠正常，大小便正常，近期无明显体重变化。 | |
[
{
"end_pos": 20,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 45,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 102,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 115,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 169,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 153
},
{
"end_pos": 320,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 316
},
{
"end_pos": 322,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 321
},
{
"end_pos": 326,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 325
},
{
"end_pos": 328,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 326
},
{
"end_pos": 330,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 328
},
{
"end_pos": 331,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 330
},
{
"end_pos": 340,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 338
},
{
"end_pos": 364,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 360
},
{
"end_pos": 371,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 366
},
{
"end_pos": 410,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 405
},
{
"end_pos": 430,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 426
},
{
"end_pos": 445,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 440
},
{
"end_pos": 464,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 459
},
{
"end_pos": 487,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 479
},
{
"end_pos": 503,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 496
},
{
"end_pos": 518,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 511
},
{
"end_pos": 522,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 519
},
{
"end_pos": 527,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 525
},
{
"end_pos": 530,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 528
},
{
"end_pos": 533,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 532
},
{
"end_pos": 550,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 547
},
{
"end_pos": 661,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 658
},
{
"end_pos": 884,
"label_type": "药物",
"overlap": 0,
"start_pos": 881
},
{
"end_pos": 895,
"label_type": "药物",
"overlap": 0,
"start_pos": 892
},
{
"end_pos": 904,
"label_type": "药物",
"overlap": 0,
"start_pos": 902
},
{
"end_pos": 915,
"label_type": "药物",
"overlap": 0,
"start_pos": 912
},
{
"end_pos": 928,
"label_type": "药物",
"overlap": 0,
"start_pos": 925
},
{
"end_pos": 973,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 968
},
{
"end_pos": 993,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 989
},
{
"end_pos": 1007,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1002
},
{
"end_pos": 1025,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1020
},
{
"end_pos": 1046,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1038
},
{
"end_pos": 1061,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1054
},
{
"end_pos": 1085,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1080
},
{
"end_pos": 1104,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1100
},
{
"end_pos": 1118,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1113
},
{
"end_pos": 1136,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1131
},
{
"end_pos": 1157,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1149
},
{
"end_pos": 1172,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 1165
},
{
"end_pos": 1219,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 1218
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2010年8月无明显诱因上出现下腹部疼痛，呈阵发性，隐痛，不剧烈，不伴恶心、呕吐、腹泻、便血、黑便、呕血等，外院查肠镜检查，未见明显异常,于2011年3月8日外院胃镜示胃体肿瘤？胃窦多发息肉（I型），，我院会诊病理示：（胃底）粘膜固有层内见异型细胞，部分呈印戒细胞样，肿瘤性病变不能除外，免疫组化考虑非霍奇金淋巴瘤，，弥漫大B细胞型：CK广（-）、CK8（-）、LCA（+++）、CD79A（+++100%）、CD20（+++100%）、CD3（少数小淋巴细胞+）、CD10（部分+）、BCL-2（+）、MUC-1（部分+）、KI-67（++90%）、CD30（++）、CD15（-）、CD56（-）、GRANB（-）。，外院腹部B超：脾稍大、肝胆囊胰体肾未见明显异常、腹腔未见明显积液。2011年3月21，外院行腹部CT示：下腹部CT增强未见明显异常。遂于2011/3/25收入我科。，入院后血常规：，红细胞计数: 4.65X10^12/L；，血红蛋白: 132G/L；，血小板计数: 168X10^9/L；，白细胞计数: 4.53X10^9/L；，中性粒细胞百分比: 66.7%；，淋巴细胞百分比: 22.7%；PET/，CT：淋巴瘤病例；胃体、胃窦局部胃壁增厚伴糖代谢异常增高，符合淋巴瘤图像表现。，骨髓穿刺涂片：骨髓增生欠活跃，髓象中红系增生尚可，粒、巨二系增生欠活跃，形态、比例均无明显异常。，骨髓活检：（骨髓）镜上为骨髓滴，免疫组化结果示，造血组织三系细胞均可见到，各系细胞形态未见明显异常，未见到淋巴瘤累及骨髓证据，请结合临床。免疫组化(11-N1436)，：MPO(粒系+) CD61(巨核+) CD68(组织细胞+) CD34(-) CD20(少数淋巴+) CD79A(少数淋巴+) CD3(少数淋巴+) CD56(-) KI-67(50%+) CYCLIND1(-) VS38C(少数+) BCL-2(少数淋巴+) CD10(-) TDT(-) 网染示网状纤维不增生。患者于2011-3-29/2011-4-29行R-CHOP方案化疗（美罗华 0.6 D0+CTX1.2 D1+盖诺40MG D1+EADM120MG D1+DEX15MG D1-D5），化疗过程中无明显不适。，患者出院后随访血常规：5/11，红细胞计数: 4.02X10^12/L；，血红蛋白:112G/L；，血小板计数:140X10^9/L；，白细胞计数:1.2X10^9/L；，中性粒细胞百分比:24.0%；，淋巴细胞百分比: 0.7%；5-18，随访血常规: 红细胞计数 4.57X10^12/L；，血红蛋白:125G/L；，血小板计数:292X10^9/L；，白细胞计数:6.3X10^9/L；，中性粒细胞百分比:83.9%；，淋巴细胞百分比: 14.6%。患者出院后无明显不适，现为行第3次化疗收入病房。患者发病以来，神清，精神可，胃纳可，二便可，体重无明显上降。 | |
[
{
"end_pos": 22,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 49,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 43
},
{
"end_pos": 65,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 79,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 100,
"label_type": "手术",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 152,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 247,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 234
},
{
"end_pos": 296,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 290
},
{
"end_pos": 343,
"label_type": "药物",
"overlap": 0,
"start_pos": 340
},
{
"end_pos": 369,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 366
},
{
"end_pos": 394,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 390
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前1年余患者因“体检发现“血PSA”升高1个月”为主诉入院，，入院后查免疫:T--PSA5.05NG/ML、F--PSA0.463NG/ML、F/T9.2。行“B超引导上经直肠前列腺穿刺活检”，恢复好，病理报告（201231203），：1.（右外侧中部），:前列腺癌GLEANSON分级III级（评分2＋3＝5分）。，免疫组化染色：灶性CK(H)、P63示腺体基底细胞消失，P504S腺体阳性。2.（右、左外侧基底部）、（左外侧中部）、（右、左外侧尖部），:前列腺增生症，伴PINI级。，免疫组化染色：CK(H)（基底细胞+），P63（基底细胞+），P504S（－）。，全身骨ECT示：未见明显异常。当时予拟手术治疗，因患者暂不想手术并要求出院，故未经手术治疗，予口服‘氟他安’治疗，并嘱其出院后定期复查。1年患者定期复查PSA均无异常。今为进一步诊疗求诊我院。门诊拟“前列腺癌”收入院。患者自发病来体重无明显变化，体力情况良好，小便如前所述，大便正常，睡眠良好，食欲一般，精神状态一般。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 87,
"label_type": "手术",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 120,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 106
},
{
"end_pos": 141,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 148,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 142
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 211
},
{
"end_pos": 215,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 214
},
{
"end_pos": 249,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 242
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。入院前2+月，因诊断结肠肿瘤于我科住院治疗，于2015年09月24日在全麻上行腹腔镜上腹腔探查术、中转开腹，右半结肠癌根治术、小肠系膜结节活检、开腹肿瘤特殊治疗、肠粘连松解术。术后病检示（病理号1508031）：右半结肠粘液性腺癌（中分化），侵及浆膜层外脂肪组织、肠系膜及网膜癌转移、肠系膜淋巴结未见癌转移（0/14），两侧切缘未见癌累及。术后予以止血、镇痛、补液、抑酸、雾化祛痰、抗感染等对症治疗。目前患者无恶心、呕吐、腹痛、腹胀、便血等表现，今日前来我院，拟行第2次化疗，故以\"右半结肠癌术后 第2次化疗\"收入我科住院治疗。 近期患者精神、食欲、睡眠可，大小便正常，体重无明显改变。 | |
[
{
"end_pos": 17,
"label_type": "手术",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 35,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 34
},
{
"end_pos": 73,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 114,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 118,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 243,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 257,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 255
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，2016.2.17行“胃癌切除术”，具体术式不详，术后病理示（远端胃及大网膜），切除：溃疡型低分化腺癌，伴印戒细胞癌，LAUREN，分型：弥漫型；癌侵及浆膜；可见脉管癌栓及神经侵犯（免疫组化CD34、D2-40证实）；十二指肠残端及胃残端未见癌；网膜组织未见癌；淋巴结可见癌转移（第1组6/12，第3组1/1，第4SB组0/0，第4D组0/1，第5组1/1，第6组6/8，第7组1/1，第8组1/3，第9组0/3，第11P组0/0，第12A组0/0，第14V组1/1）；（第1组淋巴结）其中一枚淋巴结内见异位胰腺组织；- ，肿瘤病理分期：PT4AN3B。，免疫组化结果显示肿瘤:AFP(－),CMET(1+),EBER(－),EGFR(2+),HER2(0),KI-67(+25～50%),MLH1(+＞75%),MSH2(+＞75%),MSH6(+＞75%),PDL-1(－),PMS2(+＞75%),SALL4(－),CK(+)。，淋巴结转移癌：CK（+）。入组RESOLVE A组 已行XELOX方案化疗3周期，末次化疗2016.04.11，化疗后出现恶心2度，影响进食，目前患者大小便基本正常，化疗后体重上降3KG。 | |
[
{
"end_pos": 7,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 4
},
{
"end_pos": 61,
"label_type": "手术",
"overlap": 0,
"start_pos": 20
},
{
"end_pos": 104,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 123
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 150,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 148
},
{
"end_pos": 154,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 185,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 181
},
{
"end_pos": 191,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 194,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 192
},
{
"end_pos": 201,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 278,
"label_type": "药物",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 282,
"label_type": "药物",
"overlap": 0,
"start_pos": 279
},
{
"end_pos": 291,
"label_type": "药物",
"overlap": 0,
"start_pos": 289
},
{
"end_pos": 353,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 352
},
{
"end_pos": 355,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 354
},
{
"end_pos": 360,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 358
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因卵巢癌于2016-04-12行“经腹筋膜外子宫+两附件切除+大网膜切除+阑尾切除+盆腔转移病灶清除+肿瘤细胞减灭术”，手术过程顺利，术后输液抗炎治疗。，常规病理结果示：（两侧附件）高级别浆液性乳头状癌，右卵巢肿物切面积2.8*1.5CM，左卵巢肿物切面积6*3.5CM，两侧输卵管查见癌。阑尾、“盆腔转移灶”查见癌，另送大网膜组织中查见癌。（子宫）萎缩的子宫内膜；慢性宫颈炎。右宫旁查见癌，左宫旁未查见癌。，免疫组化：ER(2+,20%),PR(1+,2%),WT-1(+),P53(-),KI67阳性率约50%。于2016-01-22给予多西他赛（多帕菲）100MG+卡铂400MG方案化疗，患者住院期间化疗毒副反应轻。今日入院，拟行第2次化疗。患者自出院后，无发热，无咳嗽咳痰，恶心呕吐轻，无腹痛腹胀，无阴道流血及排液，饮食睡眠可，大小便无异常，体重增加1KG。 | |
[
{
"end_pos": 5,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 4
},
{
"end_pos": 31,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 46,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 41
},
{
"end_pos": 60,
"label_type": "实验室检验",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 74,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 81,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 100,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 97
},
{
"end_pos": 155,
"label_type": "手术",
"overlap": 0,
"start_pos": 115
},
{
"end_pos": 200,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 211,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 220,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 216
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 224
},
{
"end_pos": 244,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 246,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 247,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 273,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 293,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 291
},
{
"end_pos": 306,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 304
},
{
"end_pos": 317,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 312
},
{
"end_pos": 337,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 325
},
{
"end_pos": 345,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 381,
"label_type": "手术",
"overlap": 0,
"start_pos": 369
},
{
"end_pos": 402,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 401
},
{
"end_pos": 449,
"label_type": "药物",
"overlap": 0,
"start_pos": 446
},
{
"end_pos": 457,
"label_type": "药物",
"overlap": 0,
"start_pos": 455
},
{
"end_pos": 489,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 486
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者因“腹痛1月余”于2011-11-17入我院，查CA125为1349U/ML，CA153为189.7U/ML，NSE为25.15NG/ML。B超提示“左侧卵巢实性占位伴中至大量腹水”，考虑“卵巢癌”，于2011-11-24行“肿瘤细胞减灭术（全子宫+两附件切除术+大网膜切除术+DIXON术+回盲部切除术）”。术程顺利，减瘤满意，残存肿瘤直径小于1CM。术后病理示：两侧卵巢见低分化浆液性腺癌浸润，脉管内见癌栓；子宫底壁外膜层、右输卵管外膜层、直肠外膜层及肌层见浆液性腺癌浸润；回盲部肠管肠壁浆膜层、肌层、粘膜上层及粘膜层均见低分化浆液性腺癌浸润，脉管内见癌栓，另见2枚淋巴结有腺癌转移；余送检、大网膜、结肠表面肿物均见低分化腺癌浸润。术后诊断“卵巢浆液性腺癌IIIC期”。术后出现肠瘘，保守治疗效果欠佳，遂于2011-12-09行“腹腔清创引流+回肠造瘘术”，术后予加强营养等治疗。一般情况恢复、腹壁切口愈合良好后于2012-01-18、2012-02-23、2012-5-17予TP（北华素180MG，波贝500MG）方案化疗3程，化疗后无明显恶心、呕吐反应，出现两脚底麻木感，予营养神经治疗后好转。今遵原主诊教授意见为行化疗入院。下次出院至今，患者精神、食欲、睡眠可，大便正常，小便顺畅，体重稍有增加。 | |
[
{
"end_pos": 11,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 27,
"label_type": "手术",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 38,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 53,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 131,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 94
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者3余月前因“胃癌”于我院在全麻上行“胃大部切除术”。，术中探查：未见腹水，P0H0，肿瘤位于胃窦小弯明显浸透浆膜外，浆膜呈皱缩上凹状部分网膜覆盖其下。，术后病理：，病理诊断：，进行期胃窦癌：BORRMANN3型 浸润深度（SE） 浸润溃疡型，低－中分化腺癌 断端无癌 ，静脉癌栓：，无 淋巴管癌栓：无 伴淋巴结转移(1/38枚) 。（，病理号：199546）。患者术后恢复良好。今为求进一步治疗，遂来我院。病来，患者饮食睡眠可，大小便正常，体重无明显减轻。 | |
[
{
"end_pos": 16,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 41,
"label_type": "手术",
"overlap": 0,
"start_pos": 33
},
{
"end_pos": 60,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 59
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 61
},
{
"end_pos": 139,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 149,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 144
},
{
"end_pos": 159,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 181,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 175
},
{
"end_pos": 241,
"label_type": "药物",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 250,
"label_type": "药物",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 286,
"label_type": "药物",
"overlap": 0,
"start_pos": 282
},
{
"end_pos": 295,
"label_type": "药物",
"overlap": 0,
"start_pos": 292
},
{
"end_pos": 331,
"label_type": "药物",
"overlap": 0,
"start_pos": 327
},
{
"end_pos": 340,
"label_type": "药物",
"overlap": 0,
"start_pos": 337
},
{
"end_pos": 372,
"label_type": "药物",
"overlap": 0,
"start_pos": 369
},
{
"end_pos": 380,
"label_type": "药物",
"overlap": 0,
"start_pos": 378
},
{
"end_pos": 411,
"label_type": "药物",
"overlap": 0,
"start_pos": 408
},
{
"end_pos": 420,
"label_type": "药物",
"overlap": 0,
"start_pos": 417
},
{
"end_pos": 455,
"label_type": "药物",
"overlap": 0,
"start_pos": 452
},
{
"end_pos": 485,
"label_type": "药物",
"overlap": 0,
"start_pos": 481
},
{
"end_pos": 500,
"label_type": "药物",
"overlap": 0,
"start_pos": 497
},
{
"end_pos": 535,
"label_type": "药物",
"overlap": 0,
"start_pos": 531
},
{
"end_pos": 550,
"label_type": "药物",
"overlap": 0,
"start_pos": 547
},
{
"end_pos": 566,
"label_type": "药物",
"overlap": 0,
"start_pos": 563
},
{
"end_pos": 597,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 593
},
{
"end_pos": 622,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 621
},
{
"end_pos": 625,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 624
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前1余年前于我院诊为胃癌，于2012-08-07在全麻上行根治术全胃切除术。术后病理（201223223）示全胃：食管胃交界溃疡型管状腺癌，II-III级，侵出浆膜层，侵犯脉管和神经。手术标本下切端见癌浸润，手术标本上切端和另送（下切端）未见癌浸润。镜上找到贲门周淋巴结3/8个、小弯淋巴结3/4个、大弯淋巴结0/1个、幽门下淋巴结0/4个和幽门上淋巴结0/1个见癌转移。术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲，并顺利出院，2012.09.24行“伊立替康280MG+替吉奥60MGBID×14D”方案化疗1周期，2012.10.23按“伊立替康280MG+替吉奥40MGBID×14D”方案化疗1周期，2012.11.20按“伊立替康240MG+替吉奥80MGBID×7D”化疗1次,2012.12.22按““安素泰210MG+艾奕40MGBID×14D”化疗1次，2013.1.18予“安素泰240MG+替吉奥40MGBID×14D”方案化疗1次，2013.02.23按T“安素泰240MG”方案化疗1周期。2014.08.28予“表柔比星70MGIVGTTD1+替吉奥40MGBID×10D”方案化疗1次，2014.09.22予“表柔比星70MGIVGTTD1+安素泰210MGIVGTTD1+替吉奥40MGBID×14D”。今为再次化疗就诊我院，门诊拟胃癌术后化疗后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 22,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 29
},
{
"end_pos": 72,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 70
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 86,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 84
},
{
"end_pos": 87,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 86
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 108,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 133,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 118
},
{
"end_pos": 144,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 136
},
{
"end_pos": 192,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 220,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 229,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 252,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 255,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 254
},
{
"end_pos": 287,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 286
},
{
"end_pos": 290,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 289
},
{
"end_pos": 300,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 299
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者4年前因\"胸中段段食管中-低分化鳞癌\"于我院行“经右胸食管癌根治+胃食管主动脉弓下吻合术”，，术后复查：2015年2月25日，我院CT检查示：食道癌术后改变，纵隔胃代食管未见明显软组织肿物。气管右侧旁淋巴结转移。，超声检查示：右侧颈部VI区及IV区小淋巴结，其中VI区最大淋巴结较前次检查（2014-11-04）增大，考虑恶性可能性大。2015年02月27日，右颈肿大淋巴结穿刺活检病理考虑：增生的纤维组织中见高至中分化鳞状细胞癌浸润，考虑为食管癌转移。现患者出现声嘶20天，考虑右颈转移淋巴结侵犯喉返神经。今为进一步诊治收入我科。起病以来，患者无发热、咳嗽，无胸闷、胸痛，无恶心、呕吐，胃纳、睡眠、精神可，大小便正常，体重无明显变化。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 69,
"label_type": "手术",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 90,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 89
},
{
"end_pos": 149,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 209,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 220,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 214
},
{
"end_pos": 232,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 226
},
{
"end_pos": 243,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 237
},
{
"end_pos": 250,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 466,
"label_type": "药物",
"overlap": 0,
"start_pos": 464
},
{
"end_pos": 480,
"label_type": "药物",
"overlap": 0,
"start_pos": 477
},
{
"end_pos": 521,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 512
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于4个月前因食管胃交界腺癌于我院行（2015.10.19）正中开腹根治性全胃切除+食管-空肠ROUX-EN-Y吻合+空肠造瘘+脾切除术，术后病理（201537413），：(全胃)，：食管-胃交界处溃疡型混合型腺神经内分泌癌【腺癌为管状腺癌II-III级，神经内分泌肿瘤为G3型（神经内分泌癌）】，浸润脉管及神经组织，脉管内见癌栓，侵出浆膜层。手术标本下切端、上切端，及另送(最下切端)均未见癌浸润。找到贲门周淋巴结1/4个，小弯侧淋巴结1/11个，大弯侧淋巴结0/6个，幽门上淋巴结0/2个。脾脏组织。，免疫组化染色结果：KI67（30%阳性），P53（++），MLH1（++），MSH-6（+++），CGA（+++），CD56（++），SY（++）。（MM2051901）该病例未检测到KRAS基因12、13号密码子热点突变。（MM20151902）该病例未检测到BRAF基因V600E突变。术后恢复良好，目前进食半流质膳食，无不适。分别于2015.11.25、2015.12.25、2016.01.21日行3周期化疗，“顺铂40MG静滴D1-3+紫杉醇180MG静滴D2”方案，今为求术后第4周期化疗再诊我院，门诊拟食管胃交界腺癌术后化疗收住我科。近来，精神、睡眠、饮食一般，大小便如常，体重无明显增减。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 83,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 82
},
{
"end_pos": 86,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 85
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 127,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 125
},
{
"end_pos": 145,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 143
},
{
"end_pos": 174,
"label_type": "手术",
"overlap": 0,
"start_pos": 167
},
{
"end_pos": 189,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 185
},
{
"end_pos": 208,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 195
},
{
"end_pos": 213,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 212
},
{
"end_pos": 464,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 463
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者5年余前因\"升结肠癌\"在外院手术治疗，术后规律完成辅助化疗（XELOX方案化疗8程），但未规律复查。近1年偶有大便带血，量少，大便不成形，1-3次/天，无腹痛、腹胀，无黑便、恶心等，未予重视。于2015-01月至外院复查肠镜发现距肛40CM结肠肿物，肠镜不能通过，活检病理提示腺癌。 于2015-01-22至我院全麻上行\"右半结肠切除术\"，，术后病理示：（乙状结肠大体）镜检为肠低分化腺癌（印戒细胞癌），浸润至肠壁浆膜上层，未见脉管内癌栓及神经束侵犯；网膜组织未见癌。区域淋巴结15/22（+），，免疫组化：ER（-），ERCC1（+），MLH1（+），MSH2（-），MSH6（-），PMS2（+），KI67（40%+），CK（+）。，术后分期：PT3N2BM0 IIIC期。于2015-03-25、2015-04-11、2015-04-28、2015-05-12及2015-05-26;2015-6-9、2015-06-23给予 FOLFOX 方案化疗7程顺利，化疗耐受性可，今为进一步治疗入院。近期患者精神胃纳睡眠尚可，大小便正常，体重无明显上降。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 51,
"label_type": "手术",
"overlap": 0,
"start_pos": 35
},
{
"end_pos": 76,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 69
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 120,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 141,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 140
},
{
"end_pos": 142,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 207,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 204
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。入院前1月，患者因确诊“食管下段鳞癌”于2016年04月11日在全麻+两腔上行经颈胸腹下段食管癌切除术、术后标本送病检（1603183）：食管鳞状细胞癌侵及全层，远近切缘均未见癌累及，贲门上淋巴结见癌转移（1/1）,胃右动脉旁、隆突上淋巴结未见癌转移，术后予以心电监护、禁食、水、胃肠减压、静脉高营养、抗感染、祛痰、解痉、护胃、止血、降血压等对症支持治疗后，好转出院。今患者为行第一次化疗来我院就诊，门诊以“食管癌”收入我科住院治疗。 自患病以来，患者精神、食欲、睡眠尚可，二便正常，体征无明显上降。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 23,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 19
},
{
"end_pos": 44,
"label_type": "手术",
"overlap": 0,
"start_pos": 27
},
{
"end_pos": 54,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 107,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 104
},
{
"end_pos": 110,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 108
},
{
"end_pos": 116,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 114
},
{
"end_pos": 121,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 133,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 131
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 194
},
{
"end_pos": 206,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 204
},
{
"end_pos": 226,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 243,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 241
},
{
"end_pos": 277,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 256
},
{
"end_pos": 301,
"label_type": "药物",
"overlap": 0,
"start_pos": 298
},
{
"end_pos": 306,
"label_type": "药物",
"overlap": 0,
"start_pos": 304
},
{
"end_pos": 308,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 306
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于69天前于我院因“，盆腔包块：卵巢CA?”行“腹腔镜上腹膜活检术+右侧卵巢切除术”，术中切除右侧卵巢及2.0CM*1.0CM大小腹膜送冰冻病理切片，2013-4-27 ，冰冻切片报告单检查报告：1、（右卵巢）卵巢组织中见腺癌。2、（腹膜）纤维脂肪组织中见腺癌。检查无活动性出血后，手术顺利，麻醉满意，术中出血约50ML，术毕安返病房。2013-4-28 ，组织病理检查报告：1、（右卵巢）送检组织中见腺癌组织，待免疫组化进一步明确类型。2、（腹膜）送检纤维脂肪组织中可见少许腺癌组织。2013-05-03（右卵巢）中-低分化宫内膜样腺癌伴腹膜转移。，术后给予：补液、抗炎对症治疗。术后给予紫杉醇静滴+顺铂腹腔灌注化疗双次，化疗过程中病员有恶心、呕吐等不适。现患者来我院要求行第3次化疗。\U0004 患者本次发病以来，食欲减退， 神志清醒，精神尚可，睡眠尚可，大便正常，小便正常，体重无明显变化。 | |
[
{
"end_pos": 20,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 13
},
{
"end_pos": 60,
"label_type": "手术",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 74,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 72
},
{
"end_pos": 87,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 137,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 159,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 146
},
{
"end_pos": 346,
"label_type": "药物",
"overlap": 0,
"start_pos": 342
},
{
"end_pos": 363,
"label_type": "药物",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 394,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 393
},
{
"end_pos": 420,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 419
},
{
"end_pos": 428,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 426
},
{
"end_pos": 432,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 431
},
{
"end_pos": 433,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 432
},
{
"end_pos": 465,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 460
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院1年前于我院诊为“直肠癌伴肝转移”，于2015年12月07日在全麻上行“腹腔镜上直肠姑息性切除术+末段回肠造瘘术”，术顺，术后病理示：（直肠）大肠溃疡型管状腺癌II级，部分为筛状粉刺型，侵出外膜层，手术标本双切端及另送(下切端)(上切端)均未见癌浸润，找到肠周淋巴结2/21个，及另送(肠系膜上动脉根部)淋巴结0/1个，见癌转移。术后恢复良好。于2015.12.30、2016.01.21、2016.02.13、2016.03.06、2016.03.30、2016.04.22、2016.05.12、2016.06.03、2016.06.27、2016.07.21、2016.08.11、2016.9.02、2016.10.27、2016.11.18、2016.12.23行“伊立替康240MGIVGTTD1+卡培他滨1500MGPOBIDD1-D14”化疗，辅以止吐、制酸、保肝、增强免疫等，化疗过程顺利，未见明显不适。出院后无头晕、乏力，无口腔溃疡、手足麻木无力等不适。此次为行第16次化疗就诊我院，门诊拟“直肠癌术后化疗”收入院。下次出院以来精神、睡眠、饮食可，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 42,
"label_type": "手术",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 109,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 139,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 142,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 153,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 156,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 155
},
{
"end_pos": 160,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 168
},
{
"end_pos": 211,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 195
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于1个多月前因食管下段癌于我院行胸腹腔镜联合全胸段食管切除+食管-胃底右颈部吻合术。手术顺利。术后病理（病理号：201607041）示食管髓质型高分化鳞状细胞癌，侵及外膜层，手术标本双切端未见癌浸润，找到食管周淋巴结1个，未见癌转移。现患者一般情况尚可，无明显恶心、呕吐，无头晕、头痛，无咳嗽、咳痰，无胸闷、胸痛，无腹痛、腹胀，无周身骨骼疼痛等不适。今为求入院第1周期化疗再诊我院，门诊拟食管癌（T3N2M0IIIB期）收住我科。近来，精神、睡眠、饮食一般，大小便如常，体重无明显增减。 | |
[
{
"end_pos": 13,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 51,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 49
},
{
"end_pos": 79,
"label_type": "手术",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 111,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 110
},
{
"end_pos": 135,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 140,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 182,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 178
},
{
"end_pos": 249,
"label_type": "药物",
"overlap": 0,
"start_pos": 245
},
{
"end_pos": 262,
"label_type": "药物",
"overlap": 0,
"start_pos": 258
},
{
"end_pos": 313,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 312
},
{
"end_pos": 316,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 315
},
{
"end_pos": 327,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 326
},
{
"end_pos": 330,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 329
},
{
"end_pos": 333,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 332
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2月余前因“反复剑突上痛3年余，加重2月。”入院，入院完善辅助检查后于2015.12.09在OR于全麻上行“远端胃切除+B-II重建+空肠BRAUN吻合”术，术后予以预防感染，对症支持治疗，恢复顺利，，术后病理:（胃大体）镜检为胃粘液腺癌，LAUREN，分型：肠型，浸润至胃壁浆膜层，可见脉管及神经束侵犯；网膜组织未见癌。切缘未见癌。淋巴结6/44见粘液腺癌转移。，免疫组化：癌细胞 HER-2（0），VEGF（+）。，原位杂交：EBERS（-）。术后于2016-01-20行SOX（奥沙利铂 150MG + 替吉奥 50MG BID）第1疗程化疗，无明显不良反应。现为行术后第二次化疗返院。自下次出院，患者无发热，无头痛、头晕，无咳嗽、咳痰，无心悸、胸闷、胸痛，无尿频、尿急。精神、睡眠可，胃纳一般，二便正常，患者体重上降2KG。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 20,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 23,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 76,
"label_type": "手术",
"overlap": 0,
"start_pos": 63
},
{
"end_pos": 101,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 106,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 102
},
{
"end_pos": 120,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 109
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 222,
"label_type": "手术",
"overlap": 0,
"start_pos": 212
},
{
"end_pos": 250,
"label_type": "药物",
"overlap": 0,
"start_pos": 248
},
{
"end_pos": 259,
"label_type": "药物",
"overlap": 0,
"start_pos": 256
},
{
"end_pos": 344,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 343
},
{
"end_pos": 353,
"label_type": "药物",
"overlap": 0,
"start_pos": 349
},
{
"end_pos": 358,
"label_type": "药物",
"overlap": 0,
"start_pos": 354
},
{
"end_pos": 361,
"label_type": "药物",
"overlap": 0,
"start_pos": 359
},
{
"end_pos": 397,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 389
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前28个月因结肠息肉行腹部CT示肝脏数个低、稍低密度灶，部分为小囊肿，部分转移瘤不能排除，并于2012.03.06行腹腔镜上乙状结肠病损切除术，术后病理(201206355)，示：(降结肠肿瘤及肠管系膜)，：肠溃疡型管状腺癌II级，侵出外膜层。手术标本双切口及另送(下切端)、(上切端)均未见癌浸润。找到肿物周淋巴结4/10个，肠周淋巴结2/8个见癌转移，术后患者恢复顺利出院。于2012-4-25在B超引导上行“左肝转移灶射频消融术”，并于2012-5-8及2012-5-30行2次“艾恒150MG+希罗达1000MGBID*14天”化疗。于2012-06-22、2012-08-24、2012-10-11、2013-01-18、2013-03-11、2013-04-08行肝动脉置管(5-FU+亚叶酸钙+艾恒)化疗，此后不定期复查。今为进一步治疗就诊于我院，门诊拟结肠癌肝转移术后介入术后收入院。目前患者精神、睡眠、饮食尚可，大小便无明显异常，体重未见明显减轻。 | |
[
{
"end_pos": 13,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 42,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 39
},
{
"end_pos": 49,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 43
},
{
"end_pos": 83,
"label_type": "手术",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 109,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 91
},
{
"end_pos": 184,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 275,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 274
},
{
"end_pos": 277,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 306,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 301
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者5月余前因“发作性胸闷、憋气半年余，加重1月余”入院，，行肠镜检查提示：结肠癌、结肠多发息肉。查无手术禁忌后于2016-11-03日在全身麻醉上行左半结肠切除术。，术后病理示：结肠腺癌（中-低度分化），浸润溃疡型，体积7.5*4*1.7CM，侵穿浆膜，未累及底部切除面及双端切线。 “一站”（7个）、“二站”（5个）、“三站”（12个）淋巴结未查见癌。慢性阑尾炎，外膜有较多中性粒细胞浸润。，癌组织免疫组化染色示：SYN（-）、BRAF（-）、MLH1（+）、MSH2（+）、MSH6（+）、PMS2（±）。院外期间患者一般情况好，无恶心，无腹痛腹胀胀不适，现患者为行复查及化疗来院就诊，门诊以“结肠癌术后”收入院。 近期患者精神可，饮食可，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 16,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 14
},
{
"end_pos": 41,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 40
},
{
"end_pos": 74,
"label_type": "手术",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 80,
"label_type": "手术",
"overlap": 0,
"start_pos": 75
},
{
"end_pos": 87,
"label_type": "手术",
"overlap": 0,
"start_pos": 81
},
{
"end_pos": 99,
"label_type": "手术",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 135,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 169,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 177,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 176
},
{
"end_pos": 339,
"label_type": "药物",
"overlap": 0,
"start_pos": 335
},
{
"end_pos": 366,
"label_type": "药物",
"overlap": 0,
"start_pos": 362
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2016年2月因“反复下腹痛4月余。”入院，入院完善辅助检查，，明确诊断：胃癌。后于2016-02-17在OR于全麻上行“腹腔镜辅助胃癌根治术（远端胃切除+B-II重建+空肠空肠Ｂｒａｕｎ吻合）”，术后予以预防感染，对症支持治疗，恢复顺利，，术后病理回报：（胃大体）镜检为中-低分化腺癌，部分为印戒细胞癌，LAUREN，分型：混合型，癌组织浸润至胃壁浆膜上层，可见脉管内癌栓及神经束侵犯。切缘未见癌。淋巴结）2/46见腺癌转移。，免疫组化：CK（+），VEGF（+），HER-2（-）。，原位杂交：EBERS（-）。 术后于2016-03-21、2016-04-11、2016-05-03、2016-05-23、2016-06-13、2016-07-05在我院行(奥沙利铂 150MG Q3W IVDRIP D1 + 替吉奥 60MG BID PO D1-14)化疗6疗程，过程顺利。现为行术后第7疗程化疗返院治疗。自下次出院以来，患者体重无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 45,
"label_type": "手术",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 107,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 168,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 139
},
{
"end_pos": 209,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 208
},
{
"end_pos": 211,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 241,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 237
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者约于1个月前因“胃癌”于2014-10-23在全麻上行根治性胃大部切除、毕I式吻合术，手术顺利，术后给予输液、抗生素及营养支持等治疗。，术后病理示：（9302.2012）胃窦大弯侧腺癌（中度分化），浸润溃疡型，面积2.5*2CM，厚2.8CM，侵达浆膜。双端切线未查见癌。四组（5个）、六组（9个）、“1、3、7组”（8个）淋巴结，未查见癌。，术后病理分期：PT4AN0M0，IIB期。院外期间，患者无发热，无腹痛腹胀不适，大便通畅。现患者为行复查化疗来我科就诊，以“胃癌术后”收入院。 病人自下次出院以来，神志清，精神可，饮食可，大、小便正常，体重未见明显变化。 | |
[
{
"end_pos": 7,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 4
},
{
"end_pos": 34,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 63,
"label_type": "手术",
"overlap": 0,
"start_pos": 58
},
{
"end_pos": 83,
"label_type": "手术",
"overlap": 0,
"start_pos": 64
},
{
"end_pos": 181,
"label_type": "药物",
"overlap": 0,
"start_pos": 177
},
{
"end_pos": 185,
"label_type": "药物",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 205,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 204
},
{
"end_pos": 206,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 205
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者因“下腹部疼痛不适，以进食后尤甚，伴返酸、嗳气”，在我院确诊胃癌，遂于2015.3.13在我院手术室全麻上行\"胃癌根治术（远端胃大部切除+ROUX-EN-Y重建）\"，术程顺利，术后恢复可。术后病理提示：T3N3M0，IIIB。 已于2015.4.3、2015.4.22、2015-05-14、2015-6-4,2015-6-26行5程化疗，方案为奥沙利铂+替吉奥，化疗期间无明显副反应，现复查血常规、肝肾功能结果基本正常。现为行上一程化疗收入我科。起病以来，患者精神尚可，食欲一般，大小便正常，身体无明显消瘦。 | |
[
{
"end_pos": 29,
"label_type": "手术",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 60,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 36
},
{
"end_pos": 366,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 364
},
{
"end_pos": 406,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 405
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者2015年9月9日于全麻上经腹腔镜直肠癌DIXON术，，术后病理：直肠癌（浆膜上层），扁平隆起型，高分化腺癌，I级，断端无癌，淋巴结可见癌转移（5/13枚），，浸润深度：浆膜上层，周围神经节侵犯（+)，脉管癌栓（-），结外肿瘤种植（-)，PTNM，分期：T3N2AM0，IIIB期，，免疫组化：KI67（50-70%+），P53(>90%+)，CDX2(>90%+)，CA199(+)，CEA(+++)，GSTP1(+++)，EGFR(+++)，VEGF(++)，MLH1(>90%+)，MSH2(>90%+)，MSH6(>90%+)，PMS2(>90%+)。血管内皮细胞CD34（+）其内未见癌栓，淋巴管内皮细胞D2-40(+)其内未见癌栓,周围神经S100（+）可见癌侵犯，，病理号：1806。术后患者恢复良好，术后行腹腔穿刺化疗一次，今为求进一步治疗收入我科。近日无发热，饮食睡眠可，大小便正常，无腹痛，无便血，近来体重未见明显变化。ECOG，评分：1分。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 53,
"label_type": "手术",
"overlap": 0,
"start_pos": 48
},
{
"end_pos": 61,
"label_type": "手术",
"overlap": 0,
"start_pos": 54
},
{
"end_pos": 102,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 95
},
{
"end_pos": 167,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 327,
"label_type": "药物",
"overlap": 0,
"start_pos": 323
},
{
"end_pos": 340,
"label_type": "药物",
"overlap": 0,
"start_pos": 336
},
{
"end_pos": 349,
"label_type": "药物",
"overlap": 0,
"start_pos": 345
},
{
"end_pos": 372,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 371
},
{
"end_pos": 423,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 419
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者3月前因“下腹部疼痛不适半年余，加重伴进食后呕吐2月余”入院,于2016-9-7在全麻上行胃癌根治术（毕-II式吻合），手术过程顺利，术后患者恢复好，切口愈合好，按期拆线。，术后病理：胃窦低分化腺癌，体积3.5*3.5*1.6CM，浸润溃疡型，侵穿浆膜。双端切线未查见癌。呈“第六组”（6/13个）、“胃第六组”（1/1）淋巴结癌转移。第三组（4个）、第四组（4个）、“胃第七组”（1个）淋巴结未查见癌。第五组查见癌结节一个。，癌组织免疫组化染色示：CERBB-2（1+）、SYN（-）、β-TUBULIN-III（-）、 RRM1个别（+）、TOPOII（+）。根据患者病情具有化疗指征，于2016-09-25开始第一周期化疗，，方案为：奥沙利铂200MG D1，亚叶酸钙0.3G+氟尿嘧啶0.75G D2-D6，同时给与升白细胞、护肝、止吐、免疫增强治疗，患者化疗耐受可，无明显化疗副反应。现患者为求明确诊疗来我院就诊，门诊以“胃癌术后”收入我科。 患者自发病以来，精神可，饮食欠佳，睡眠可，二便正常，体重减轻约14KG。体力无明显改变。 | |
[
{
"end_pos": 11,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 54,
"label_type": "手术",
"overlap": 0,
"start_pos": 44
},
{
"end_pos": 112,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 172,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 197,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 301,
"label_type": "药物",
"overlap": 0,
"start_pos": 297
},
{
"end_pos": 314,
"label_type": "药物",
"overlap": 0,
"start_pos": 310
},
{
"end_pos": 329,
"label_type": "药物",
"overlap": 0,
"start_pos": 325
},
{
"end_pos": 375,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 371
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者4月前因“下腹部疼痛不适10余年，加重1月余”入院，2016-06-02在全麻上行胃癌根治+幽门成形术，手术过程顺利，术后患者恢复好，切口愈合好，按期拆线。，术后病理：（201611546），：胃体小弯腺癌（中度分化），局部伴神经内分泌分化，体积2*1*0.5CM，溃疡型，侵达浅肌层。双端切线及另送“近切线”未查见癌。 呈“三组”淋巴结（8/13个）淋巴结癌转移。“四组”（5个）淋巴结未查见癌。 ，癌组织免疫组化染色示：TS部分（+）、TOPOII多数（+）、β-TUBULIN-III少数（+）、 RRM1（-）、SYN部分（-）、CERBB-2（-）。术后给予辅助化疗，，方案为：奥沙利铂150MG D1+亚叶酸钙0.3G D2-6 +氟尿嘧啶750MG D2-6 静滴。现患者为求复查化疗来我院就诊，为行进一步治疗，门诊以\"胃癌术后\"收入我科。 患者自发病以来，精神可，饮食可，睡眠可，二便正常，体重体力无明显改变。 | |
[
{
"end_pos": 14,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 11
},
{
"end_pos": 28,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 26
},
{
"end_pos": 72,
"label_type": "手术",
"overlap": 0,
"start_pos": 46
},
{
"end_pos": 83,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 81
},
{
"end_pos": 94,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 93
},
{
"end_pos": 98,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 96
},
{
"end_pos": 100,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 99
},
{
"end_pos": 115,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 141,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 132
},
{
"end_pos": 173,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 174
},
{
"end_pos": 200,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 199
},
{
"end_pos": 216,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 203
},
{
"end_pos": 267,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 261
},
{
"end_pos": 277,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 272
},
{
"end_pos": 288,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 283
},
{
"end_pos": 299,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 293
},
{
"end_pos": 319,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 308
},
{
"end_pos": 336,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 331
},
{
"end_pos": 400,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 399
},
{
"end_pos": 403,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 402
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于1月前因“反复中下腹闷痛不适3月”入院，诊为胃癌，于2013年12月10日在全麻上行根治性全胃切除术+食管空肠ROUX-Y吻合术（D2），手术顺利。术中见腹腔内无明显粘连，无明显腹水，盆腔、腹壁、大网膜无明显转移结节，肝脏表面光滑，未见明显转移灶，肿瘤位于贲门胃体下段小弯侧，侵出浆膜层，活动度可，周围可及明显肿大淋巴结，主要位于胃小弯侧及胃右动脉旁。术后病理（201339038），：（全胃），：食管胃交界溃疡型低分化腺癌，侵出浆膜层，侵犯神经，脉管内见癌栓，手术标本下、上切端及另送（下切端）均未见癌浸润，找到贲门左淋巴结1/2个，小弯淋巴结5/11个，大弯淋巴结0/1个，幽门上淋巴结0/3个，及另送的（胃右动脉根部）淋巴结2/5个见癌转移。另送（脾门淋巴结）为纤维、脂肪组织。术后给予对症、抗感染治疗，恢复良好,伤口愈合II/甲。此次为术后第1次化疗入院。患者出院后饮食、夜休可，无腹痛、腹胀、发热，体重较前无明显变化。 | |
[
{
"end_pos": 14,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 40,
"label_type": "手术",
"overlap": 0,
"start_pos": 32
},
{
"end_pos": 81,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 73
},
{
"end_pos": 152,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 138
},
{
"end_pos": 163,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 157
},
{
"end_pos": 268,
"label_type": "药物",
"overlap": 0,
"start_pos": 264
},
{
"end_pos": 281,
"label_type": "药物",
"overlap": 0,
"start_pos": 277
},
{
"end_pos": 290,
"label_type": "药物",
"overlap": 0,
"start_pos": 286
},
{
"end_pos": 313,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 312
},
{
"end_pos": 349,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 348
},
{
"end_pos": 351,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 350
},
{
"end_pos": 395,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 388
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者约于5月前因“乙状结肠癌”于2017-02-07在全麻上行乙状结肠癌根治术，手术过程顺利，术后患者恢复好，切口愈合好，按期拆线。，术后病理:（乙状结肠）腺癌，中、低度分化，浸润溃疡型，体积5*3*1.3CM，侵穿浆膜， 双端切线及另送“近切线”、“远切线”未查见癌。 呈肠壁一站（4/10个）淋巴结癌转移。 中间组淋巴结（1个）未查见癌。，免疫组化染色示：SYN（-）、BRAF（-）、MLH1（+）、MSH2（+）、 MSH6（+）、PMS2（+）。查无化疗禁忌后于2017-03-05开始给予规律化疗5周期，，方案为：奥沙利铂200MG D1，亚叶酸钙0.3G+氟尿嘧啶0.75G D2-D6，同时给与升白细胞、护肝、止吐、免疫增强治疗，患者副反应轻。院外期间患者一般情况好，无恶心，无腹痛腹胀不适，1天前患者发现白细胞低，现患者为行复查及化疗再次来院就诊，门诊以“乙状结肠癌术后”收入院。 发病以来，患者精神好，饮食好，睡眠好，小便正常，体重无明显改变。 | |
[
{
"end_pos": 12,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 27,
"label_type": "手术",
"overlap": 0,
"start_pos": 17
},
{
"end_pos": 76,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 85,
"label_type": "手术",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 171,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 127
},
{
"end_pos": 194,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 193
},
{
"end_pos": 259,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 246
},
{
"end_pos": 266,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 260
},
{
"end_pos": 396,
"label_type": "药物",
"overlap": 0,
"start_pos": 392
},
{
"end_pos": 408,
"label_type": "药物",
"overlap": 0,
"start_pos": 404
},
{
"end_pos": 424,
"label_type": "药物",
"overlap": 0,
"start_pos": 420
},
{
"end_pos": 439,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 438
},
{
"end_pos": 442,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 441
},
{
"end_pos": 501,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 500
},
{
"end_pos": 505,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 504
},
{
"end_pos": 507,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 506
},
{
"end_pos": 511,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 510
},
{
"end_pos": 560,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 555
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者6月余前因“直肠癌”在我院行直肠癌DIXON手术，手术过程顺利，术后给予抗感染、营养支持并补液治疗，患者2017-02-15因“直肠癌术后吻合口瘘”行“横结肠造口术”，手术过程顺利，术后给予抗感染、营养支持、补液及对症治疗，，术后病理检查结果回示：（直肠）腺癌（中、低度分化，局部伴神经内分泌分化；部分为粘液腺癌，约占30%）， 隆起型，体积2*2*1.5CM，局部侵达深肌层，并肠壁外脂肪组织内查见癌转移 灶（1处），长径约0.7CM，双端切线及另送“近切线”、“远切线”未查见癌。 多发性增生性（锯齿状）息肉。 一站淋巴结（8个）未查见癌。，癌组织免疫组化染色示：SYN局部（+）、BRAF（-）、MSH2（+）、MSH6（+）、 MLH1（+）、PMS2（+）。病情稳定后出院.患者于2017-6-2、2017-7-2及2017-7-30来我院入住我科，排除化疗禁忌后给予奥沙利铂200MGD1+氟尿嘧啶0.75G D2-D6+亚叶酸钙0.3G D2-D6，辅以保肝、护胃、止吐等对症支持治疗，过程顺利，患者耐受可，化疗结束后出院。 出院后患者病情稳定，无发热畏寒，无恶心呕吐，无咳嗽胸闷，无腹胀腹泻以及腹痛，精神好，饮食好，睡眠好，小便正常，体重无明显改变。现患者为求进一步治疗入院，门诊以“直肠癌术后”收入院。 | |
[
{
"end_pos": 20,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 18
},
{
"end_pos": 26,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 43,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 42
},
{
"end_pos": 88,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 83
},
{
"end_pos": 119,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 117
},
{
"end_pos": 123,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 184,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 182
},
{
"end_pos": 212,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 210
},
{
"end_pos": 225,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 220
},
{
"end_pos": 256,
"label_type": "手术",
"overlap": 0,
"start_pos": 251
},
{
"end_pos": 273,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 267
},
{
"end_pos": 337,
"label_type": "药物",
"overlap": 0,
"start_pos": 333
},
{
"end_pos": 341,
"label_type": "药物",
"overlap": 0,
"start_pos": 338
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者于2012-11无明显诱因出现下腹不适，轻度腹痛，与饮食无关，伴嗳气，无反酸、腹胀、恶心、呕吐及黑便。2012-11-9，就诊*********行电子胃镜检查：胃窦小弯侧见一巨大溃疡，大小约4.0X4.0CM,周围粘膜红肿，累及胃角，，胃窦活检病理为：粘膜慢性炎伴溃疡形成，局部腺体排列紊乱，不排外恶变可能.2012-11-22，入**三院行电子胃镜检查示：胃角结构破坏，可见一3X3CM巨大溃疡，底部凹凸不平，，胃角粘膜活检病理为：低分化腺癌。后转我院就诊，于2012-12-14日在全麻上行“胃癌根治术”术程顺利，术后病理为胃低分化腺癌，浸润至浆膜层，淋巴结7(+)/34，后遵原主诊医师意见2013-01-06、2013-01-25、2-25、3-15予多西他赛＋S-1”化疗3程，过程顺利。现为上一程化疗入院，起病以来，精神、饮食、睡眠尚可，大小便正常，体重无明显上降。 | |
[
{
"end_pos": 32,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 30
},
{
"end_pos": 40,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 38
},
{
"end_pos": 84,
"label_type": "手术",
"overlap": 0,
"start_pos": 80
},
{
"end_pos": 137,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 135
},
{
"end_pos": 163,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 154
},
{
"end_pos": 216,
"label_type": "手术",
"overlap": 0,
"start_pos": 202
},
{
"end_pos": 228,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 222
},
{
"end_pos": 253,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 252
},
{
"end_pos": 306,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 304
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者3个多月前因“大便习性改变4个月。”到我院就诊，经肠镜、MR等检查考虑为直肠肿物，侵犯粘膜上层，经多次表面活检及穿刺病理均未见癌。2016-3-11全麻上行TEM术，术中见肿物巨大，并与固有肌层粘连，予粘膜上层分离并分块切除。术中冰冻病理报告未见癌。术后石蜡病理提示腺癌，侵犯粘膜肌层并有中断。术后诊断为腺癌PT1N0M0。考虑肿物基底为下次肠镜息肉切除后疤痕，可能有残留，2016-5-21全麻上行腹腔镜DIXON+回肠造瘘术，术后病理：肠壁及淋巴结未见癌残留。术后恢复较慢。出院后造口排液较稀，无腹痛、发热等其他不适。现为造口回纳收入院。自下次出院以来，患者无恶心、呕吐等，无发热、咳嗽、身目黄染，无骶部痛等，精神可，纳眠可，小便无异常，体重上降月8KG。 | |
[
{
"end_pos": 14,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 46,
"label_type": "手术",
"overlap": 0,
"start_pos": 31
},
{
"end_pos": 56,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 53
},
{
"end_pos": 76,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 57
},
{
"end_pos": 126,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 121
},
{
"end_pos": 136,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 131
},
{
"end_pos": 147,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 141
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 152
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 166
},
{
"end_pos": 188,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 179
},
{
"end_pos": 208,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 200
},
{
"end_pos": 336,
"label_type": "药物",
"overlap": 0,
"start_pos": 332
},
{
"end_pos": 348,
"label_type": "药物",
"overlap": 0,
"start_pos": 344
},
{
"end_pos": 358,
"label_type": "药物",
"overlap": 0,
"start_pos": 355
},
{
"end_pos": 417,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 413
},
{
"end_pos": 441,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 440
},
{
"end_pos": 444,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 443
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前9月于我院诊为胃癌，于2014-02-24在全麻上行腹腔镜上根治性远端胃大部切除术，术后病理示（远端胃）胃窦小弯侧溃疡型管状腺癌II-III级，侵出浆膜层，侵犯神经，脉管内见癌栓，手术标本下、上切端及另送（下切端）均未见癌浸润。找到小弯淋巴结3/9个，大弯淋巴结4/6个，幽门下淋巴结0/5个，幽门上淋巴结0/3个，及另送（第8组）淋巴结1/2个，（第15组）淋巴结0/1个见癌转移。另送（第14V组淋巴结）为脂肪、纤维及脉管组织。免疫组化结果：CK7（+++），CK20（-），VILLIN（+++），CEA（+++），CDX-2（灶+），CGA（-），CD56（-），SY（-），KI67（30%+），HER-2（++）。术后恢复情况良好，术后已予“奥沙利铂200MGD1+多柔比星60MGD1+替吉奥60MGBIDD1-D14”方案化疗6周期，过程顺利，效果良好，未见明显化疗副反应。此次为复查就诊我院，门诊拟胃癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。 | |
[
{
"end_pos": 8,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 5
},
{
"end_pos": 38,
"label_type": "手术",
"overlap": 0,
"start_pos": 25
},
{
"end_pos": 102,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 76
},
{
"end_pos": 175,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 283,
"label_type": "药物",
"overlap": 0,
"start_pos": 279
},
{
"end_pos": 295,
"label_type": "药物",
"overlap": 0,
"start_pos": 291
},
{
"end_pos": 305,
"label_type": "药物",
"overlap": 0,
"start_pos": 301
},
{
"end_pos": 347,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 346
},
{
"end_pos": 349,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 348
},
{
"end_pos": 379,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 374
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，患者因“直肠癌”于2017-02-17在全麻上行直肠癌根治术(DIXON)，术后给予抗感染、营养支持、抑酸治疗，患者恢复好，切口愈合良好。，术后病理：直肠腺癌（中、低度分化），部分呈粘液腺癌分化，隆起型，体积9*9*2.5CM，侵穿浆膜，于外膜脂肪组织内查见一处癌转移灶。双端切线及另送“近切线”、“远切线”未查见癌。呈“一站”（1/12个）淋巴结癌转移。 “中央组”（2个）、“中间组”（1个）未查见癌。，免疫组化染色示：SYN（-）、BRAF（-）、MLH1（+）、MSH2（+）、MSH6（+）、PMS2（+）。 2017-03-17开始化疗，方案为奥沙利铂200MGD1，亚叶酸钙300MG+氟尿嘧啶750MG D2-D6，化疗期间有恶心、无呕吐，院外期间患者一般情况好，无恶心，无腹痛腹胀不适，现患者为行复查及化疗再次来院就诊，门诊以“直肠癌术后”收入院。 近期患者精神可，饮食可，大便次数多，小便正常，近期体重无明显变化。 | |
[
{
"end_pos": 18,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 15
},
{
"end_pos": 58,
"label_type": "手术",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 70,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 79,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 89,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 87
},
{
"end_pos": 105,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 103
},
{
"end_pos": 115,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 122,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 120
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 133
},
{
"end_pos": 190,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 187
},
{
"end_pos": 214,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 193
},
{
"end_pos": 259,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 253
},
{
"end_pos": 271,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 265
},
{
"end_pos": 282,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 276
},
{
"end_pos": 293,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 287
},
{
"end_pos": 312,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 301
},
{
"end_pos": 447,
"label_type": "药物",
"overlap": 0,
"start_pos": 443
},
{
"end_pos": 451,
"label_type": "药物",
"overlap": 0,
"start_pos": 448
},
{
"end_pos": 468,
"label_type": "药物",
"overlap": 0,
"start_pos": 465
},
{
"end_pos": 550,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 528
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前4月余在我院诊为“胃窦癌”，于2015年07月21日在全麻上行根治性远端胃切除、胃空肠ROUX-Y吻合术（D2）。，术中见：腹腔内无明显腹水，腹腔内未见转移结节，肝脏质地大小正常，未见明显肿物，胆囊无肿大。病灶位于胃角处向下侵犯胃体中段，明显侵出浆膜面，胃右动脉附近可见一肿大淋巴结，大小约3.0×3.0右左。手术顺利。术后病理（201526673），示:1.(远端胃)，：胃体前壁及胃窦溃疡型管状腺癌II-III级，伴坏死，侵出浆膜层。手术标本下切端、上切端及另送(下切端)均未见癌浸润。找到小弯侧淋巴结1/10个，大弯侧淋巴结0/4个，幽门下淋巴结0/1个，幽门上淋巴结1/6个，及另送(胃右动脉根部)淋巴结0/2个，见癌转移。，免疫组化染色结果：CGA（-），CD56（-），SY（-），KI67（60%阳性），CK(PAN)（+++），HER-2（-）；术后预防性抗感染、补液、营养等对症治疗，恢复良好后出院。术后分别于2015.09.21、2015.10.26予“奥沙利铂（乐沙定）200MGIVGGTD1+希罗达1500MGPOBIDD1-14”方案化疗2个周期。化疗过程顺利，无特殊不适。今为行第3次化疗，再次就诊于我院，门诊拟“胃管状腺癌术后（PT4AN1M0IIIA期）化疗”收入住院。自下次出院以来，精神可，睡眠可，饮食稍差，大、小便正常，体重无明显变化。 | |
[
{
"end_pos": 12,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 9
},
{
"end_pos": 35,
"label_type": "手术",
"overlap": 0,
"start_pos": 16
},
{
"end_pos": 64,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 52
},
{
"end_pos": 68,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 67
},
{
"end_pos": 95,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 90
},
{
"end_pos": 128,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 127
},
{
"end_pos": 130,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 129
},
{
"end_pos": 194,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 193
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。入院前３月，患者因直肠癌于本院行腹腔镜辅助上直肠癌根治术（MILES），手术顺利。术后组织病理检查报告示直肠溃疡型中分化管状腺癌，浸及肠壁全层，可见神经侵犯及癌栓。切端未见癌累及。肠壁淋巴结可见癌转移（1/2）。术后患者恢复好，无畏寒发热，无恶心呕吐，无腹胀腹痛，造瘘口排便排气通畅，已行FOLFOX方案化疗2次，为求术后第３次化疗于今日入院。\U0004 患者自起病以来，精神可，胃纳可，大便如常，小便如常，体重未见明显上降。 | |
[
{
"end_pos": 18,
"label_type": "手术",
"overlap": 0,
"start_pos": 12
},
{
"end_pos": 39,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 24
},
{
"end_pos": 102,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 92
},
{
"end_pos": 128,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 113
},
{
"end_pos": 210,
"label_type": "药物",
"overlap": 0,
"start_pos": 207
},
{
"end_pos": 213,
"label_type": "药物",
"overlap": 0,
"start_pos": 211
},
{
"end_pos": 237,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 233
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，2012-11-30行右乳癌根治术，术后病理示（右）乳腺浸润性导管癌，II级，大小1.8×XXX1.7×XXX1.5CM，未见脉管癌栓；乳头及皮肤未见特殊。，肿瘤病理分期：PT1C。（右腋窝前哨）淋巴结未见癌转移（0/1）；（右腋窝前哨及导丝定位）淋巴结未见癌转移（0/2）。，免疫组化染色结果：CK(-)。，免疫组化：ER(+>75%),PR(+约20%），HER-2（1+）。术后CEF方案化疗6周期，现口服来曲唑（芙瑞）内分泌治疗。 5-20本院胃镜检查提示慢性胃炎，HP(-)。现恶心未吐，进食少，大便可，睡眠差。 | |
[
{
"end_pos": 15,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 10
},
{
"end_pos": 35,
"label_type": "手术",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 71,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 55
},
{
"end_pos": 110,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 105
},
{
"end_pos": 134,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 123
},
{
"end_pos": 170,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 169
},
{
"end_pos": 172,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 171
},
{
"end_pos": 174,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 173
},
{
"end_pos": 189,
"label_type": "药物",
"overlap": 0,
"start_pos": 186
},
{
"end_pos": 245,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 244
},
{
"end_pos": 248,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 247
},
{
"end_pos": 251,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 250
},
{
"end_pos": 298,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 281
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。缘于入院前4年余因“乙状结肠癌”于我院行“腹腔镜辅助上乙状结肠癌根治术”，术后病理(201131862)回报“(乙状)结肠蕈伞型管状腺癌II级，侵及浆膜层，手术标本下、上切端及另送(下、上切端)未见癌浸润，找到肠周淋巴结11个均未见癌转移，另送(肠系膜上动脉根部淋巴结)为脂肪脉管结缔组织”，术后恢复良好出院，出院后于门诊定期复查期间发现肝、肺、骨多发转移。3年前开始口服希罗达及中药治疗（具体不详），治疗期间未诉不适。入院前2天患者无明显诱因出现纳差，并逐渐出现乏力感，无恶心、呕吐，无腹痛、腹胀、腹泻，无发热、畏寒等不适，今为求进一步诊治，就诊我院，门诊拟“乙状结肠癌术后伴肝、骨、肺多发转移”收治入院，自发病以来，饮食较差，睡眠可，二便正常，体重较前无明显改变。 | |
[
{
"end_pos": 25,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 21
},
{
"end_pos": 61,
"label_type": "手术",
"overlap": 0,
"start_pos": 50
},
{
"end_pos": 69,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 68
},
{
"end_pos": 72,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 71
},
{
"end_pos": 78,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 77
},
{
"end_pos": 81,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 79
},
{
"end_pos": 91,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 88
},
{
"end_pos": 117,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 116
},
{
"end_pos": 161,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 159
},
{
"end_pos": 175,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 164
},
{
"end_pos": 218,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 213
},
{
"end_pos": 237,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 225
},
{
"end_pos": 401,
"label_type": "影像检查",
"overlap": 0,
"start_pos": 395
},
{
"end_pos": 404,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 403
},
{
"end_pos": 429,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 428
},
{
"end_pos": 435,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 434
},
{
"end_pos": 442,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 440
},
{
"end_pos": 444,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 442
},
{
"end_pos": 465,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 459
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。，缘于入院前[主诉单一时间1年于我院诊断“降结肠癌”，查无禁忌后，于2014年04月28日在全麻上行腹腔镜上右半结肠切除术。，术中见：无腹水，肝表面光滑，胃及空肠未见明显病变。降结肠可见一大约2*3CM隆起型肿物，质硬，侵出浆膜层，肠系膜根部未见明显肿大淋巴结，术顺，术后予抗炎、制酸、补液等对症治疗，，术后病理示：（结肠），：肠隆起型管状腺癌II级，侵及粘膜上层，手术标本双切端及另送（下切端）、（上切端）均未见癌浸润；找到肠周淋巴结14个，及另送（肠系膜动脉根部）淋巴结2个，均未见癌转移。，免疫组化结果：KI67（40%阳性），P53（-），P170（+），GSTπ（+），EGFR（-），5-FU（++），MLH1（++），MSH6（++），MGMT（++）。该病例未检测到BRAF基因V600E突变、未检测到KRAS基因12、13号密码子热点突变。术后恢复良好。1周前患者于我院行PET-CT提示肝转移，无寒战、发热，无恶心、呕吐，无反酸、嗳气、腹胀、消瘦、头晕、乏力、皮肤巩膜黄染再次。就诊于我院，遂门诊拟降结肠癌术后收入院。自发病以来，精神、睡眠、食欲尚可，大便如下述，小便正常，体重无明显变化。 | |
[
{
"end_pos": 13,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 8
},
{
"end_pos": 42,
"label_type": "手术",
"overlap": 0,
"start_pos": 37
},
{
"end_pos": 72,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 60
},
{
"end_pos": 104,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 100
},
{
"end_pos": 158,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 134
},
{
"end_pos": 190,
"label_type": "解剖部位",
"overlap": 0,
"start_pos": 162
},
{
"end_pos": 316,
"label_type": "药物",
"overlap": 0,
"start_pos": 312
},
{
"end_pos": 329,
"label_type": "药物",
"overlap": 0,
"start_pos": 325
},
{
"end_pos": 343,
"label_type": "药物",
"overlap": 0,
"start_pos": 340
},
{
"end_pos": 414,
"label_type": "疾病和诊断",
"overlap": 0,
"start_pos": 410
}
] | 请你用中文完成中文电子病历命名实体识别任务，实体共有“疾病和诊断、手术、药物、解剖部位、实验室检查、影像检查”六类。患者1月余前因“胃恶性肿瘤”于我院就诊，于2016-10-25在全麻上行“胃癌根治术”，手术顺利，术后恢复良好，术后病理胃窦小弯腺癌（中度分化），体积4*3.5*1.4CM，浸润溃疡型，侵达浆膜，累及十二指肠，于部分脉管中查见癌栓，未累及近端切线。距远端切线甚近。呈“五组”（1/1个）、“第六组”（2/2个）淋巴结癌转移。四组（7个）、六组（7个）、“一三七组”（10个）淋巴结未查见癌。免疫组化染色示癌组织：CERBB-2（2+）、SYN（-）、β-TUBULIN-III（-）、RRM1少数（+）、TOPOII多数（+）、CD34血管（+）、D2-40淋巴结（+）。结合患者病情及肿瘤病理与分期继续予行术后化疗，给予“奥沙利铂200MG D1+亚叶酸钙0.3G D2-6 +替加氟1000MG D2-6 静滴”方案化疗，同时辅以镇吐、升血、免疫调节等对症支持治疗，恢复良好出院。今为行第二次化疗于我科就诊，门诊以“胃癌术后”收入院。 患者自发病以来，精神情绪及体力良好，食欲、饮食、睡眠好，小便正常。体重无明显变化。 |
End of preview. Expand
in Dataset Viewer.
README.md exists but content is empty.
Use the Edit dataset card button to edit it.
- Downloads last month
- 35